Background to the Invention Many of the actions of growth factors on cells are thought to be mediated by a family of inositol phosphoglycan (IPG) second messengers. It is believed that the source of such IPGs is a"free"form of glycosyl phosphtidylinositol (GPI) present in cell membranes.

IPGs are thought to be released by the action of phophatidylinositol-specific phospholipases following ligation of growth factors to receptors on the cell surface. There is evidence that IPGs mediate the action of a large number of growth factors including insulin, nerve growth factor, hepatocyte growth factor, insulin- like growth factor I (IGF-I), fibroblast growth factor, transforming growth factor , the action of IL-2 on B- cells and T-cells, ACTH signalling of adrenocortical cells, IgE, FSH and hCG stimulation of granulosa cells, thyrotropin stimulation of thyroid cells and cell proliferation in the early developing ear and rat mammary gland.

The family of IPG second messengers can be divided into two distinct sub-families, A-type and P-type, on the basis of biological activity. The A-type modulate the activity of a number of insulin-dependent metabolic

effects such as acetylCoA carboxylase (activates), cAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and cAMP phosphodiesterases (stimulates). In contrast, the P-type modulate the activity of enzymes such as pyruvate dehydrogenase phosphatase (stimulates) and glycogen synthase phosphatase (stimulates). The A- type mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mimic the glycogenic activity of insulin on muscle Soluble IPG fractions have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle, brain, adipose and heart) and bovine liver.

Until recently, however, it has not been possible to isolate single purified components from tissue-derived IPG fractions, much less in sufficient quantities to allow structural characterisation. Accordingly, prior art studies have been largely based on the biological activities of the fractions, with only speculation, based on indirect evidence from metabolic labelling and cleavage techniques, as to the identity of the active components.

In W098/11116 and W098/11117, we describe the isolation of active components of A-type and P-type IPG fractions from human liver and placental tissue. The biological activity of these isolates is confirmed, and certain aspects of their structure (for instance, mass spectrometry data) and properties are disclosed. A-type substances are defined, for instance, as cyclitol- containing carbohydrates which also contain Zn2+ ions and optionally phosphate; P-type substances are said to be cyclitol-containing carbohydrates which also contain Mn2+ and/or Zn2+ ions and optionally phosphate.

Other studies indicate that A-type IPGs are composed of myo-inositol, non-acetylated D-glucosamine, D-galactose and phosphate""', and P-type of chiro-inositol, non- acetylated D-galactosamine, D-mannose and phosphatel7].

We have also obtained, from large quantities of bovine liver, a partially purified glycolipid fraction that after treatment with bacterial phosphatidylinositol specific phospholipase C gave a water soluble fraction that inhibited cAMP dependent protein kinase. This biologically active material could be partially sequenced and the results indicated the presence of a family of substances containing myo-inositol, non-acetylated D- glucosamine, an undetermined hexose (either D-mannose or D-galactose), and a terminal N-acetyl-D-glucosamine residue. In addition up to four a-D-galactopyranosyl units and up to three phosphate groups seemed to be present"'.

These partial data go some way towards determining the chemical structure of the A-type IPGs, but still leave a considerable number of uncertainties. Nevertheless, it would be desirable to synthesise IPG analogues with activities at least partially mimicking those of the naturally occurring materials. To this end, we have carried out the synthetic, structural and biological <BR> <BR> <BR> <BR> studies documented in the art"', as a result of which a number of basic sub-structures have been synthesised, their shapes and spectroscopic properties studied and aspects of their potential biological activity investigated. For instance, we have synthesised inositol-containing disaccharides such as those referred to as compounds C3 (1-D-6-O-(2-amino-2-deoxy-a-D- glucopyranosyl)-myo-inositol 1,2- (cyclic phosphate)) and C4(1D-6-O-(2-amino-2-deoxy-α-D-glucopyranosyl)-chiro- inositol 1-phosphate)l9. lsy and demonstrated biological

activity, in the form of proliferative effects on the early developing inner ear of a chick embryo, for at least the myo-inositol-containing C3 Frick et al also disclose the synthesis of IPG analogues, both trisaccharides and hexasaccharides, which include mannose, glucosamine and inositol units. They conclude that a mannose side chain is necessary to maximise the insulin-mimetic activity of their products.

Summary of the Invention The present invention arises from the design and synthesis of novel hexasaccharides of the general formula I: wherein: -each R is independently selected from hydrogen, an alkyl or substituted alkyl group, an acyl or substituted acyl group, a phosphate group (P03-or P03H for instance) or a protecting group, or two of the R groups may be cyclic phosphate; -NX group represents N3; or in the NX group, X represents one or more groups independently selected from hydrogen, alkyl or substituted alkyl, acyl or substituted acyl, -NY represents a phthalimido group (NPht) or N3; or

in the NY group, Y represents one or more groups independently selected from hydrogen, alkyl or substituted alkyl, acyl or substituted acyl; or a salt or derivative of said compound.

Thus, in the compounds of formula I, the NX and NY groups may be phthalimido group (NPht) or N3, a secondary amine (-NRlH), tertiary amine (-NRlR2) or quaternary amine group (-N+RlR2R3), an amidino group (RlCONR2-) where X or Y is an acyl or substituted acyl group. In these formulae, Rl, R,, R3 in the NX or NY groups are independently selected from hydrogen or Cl-Clo alkyl or substituted alkyl, more preferably Cl-C5 alkyl. Preferred substituents include phthalimido group (NPht), N3, NH3+ and AcHN.

Preferably, the compounds represented by formula I, contain no more than three phosphate groups.

The constituent saccharide units in I are labelled a-f, and in the following description the R groups are referred to according to their positions within each unit, e. g. R2a indicates the R group at position 2 in unit a.

Compound I contains the basic saccharide units believed to be present in A-type IPGs, i. e. a myo-inositol unit (a), a non-acetylated D-glucosamine unit (b), a mannose unit (c), a terminal N-acetyl-D-glucosamine residue (d) and D-galactose units (e) and (f). It also has a reasonable structural overlap with the conserved linear glycan chain of the GPI anchors depicted as formula 2 in Figure 1. Thus, taking into account the immunological evidence that antibody probes generated against 2 cross react with IPGs from rat liver and block some of the effects of insulin compound I can reasonably be

expected to be useful as a synthetic analogue, or mimetic, of naturally-occurring A-type IPGs, and hence to have applications in pharmaceutical compositions and methods.

Other aspects of the invention relate to methods for synthesising compounds of formula I and to intermediate compounds generated during the syntheses.

Detailed Description Compounds of Formula I The first aspect of the invention provides a compound of formula I, as defined above, or a salt or other derivative thereof.

In formula I, where R is an alkyl or acyl groups, or substituted versions thereof (e. g. with halogeno, cyano, amino, carbonyl, and/or carboxy groups etc) it is preferably Cl-Clo, and more preferably Cl-C5, and may be primary, secondary or tertiary.

The NX and NY groups may be phthalimido group (NPht) or N3, a secondary amine (-NR1H), tertiary amine (-NR1R2) or quaternary amine group (-N+RlR2R3), an amidino group (R1CONR2-) where X or Y is an acyl or substituted acyl group. In these formulae, Ri, R2, R3 in the NX or NY groups are independently selected from hydrogen or Cl-Cl0 alkyl or substituted alkyl, more preferably Cl-C5 alkyl.

As used herein,"salt"includes physiologically acceptable salts meaning pharmaceutically applicable or non-toxic salts. Such salts are formed by compounds of Formula I with acid groups, e. g. carboxyl, with alkali and alkaline earth metals such as Na, K, Mg and Ca, and with physiologically acceptable organic amines, e. g.

triethylamine and tris (2-hydroyethyl) amine. Compounds of Formula I containing basic groups, e. g. an amino group or guanidino groups (and especially NX or NY groups where X and/or Y are hydrogen) form salts with inorganic acids, e. g. hydrochloric acids, sulphuric acid, acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid and p-toluenesulphonic acid. Compounds with equal numbers of acid and base groups can form internal salts and do not need a third salt component.

"Derivative"includes coordination complexes, for example with metal ions such as Zon". It also includes so-called "prodrug"forms of the compound, convertible either in vitro or in vivo into compounds of formula I. An example of a suitable prodrug is a glycolipid derivative in which Rla i s: diacyl glycerol, which may be convertible to I following phospholipase cleavage.

As set out above, the compounds of the invention may also include one or more groups for protecting hydroxyl or phosphate groups. Phosphate protecting group such as phenyl, benzyl or hydroxypropylnitrile (Hoeben-Weyl, Methods of Organic Chemistry, volume 12/1 or 12/2, Teilheimer, Synthetic Methods of Organic Chemistry, Vol 45). Protecting groups for the OH of sugars including benzyl, acetyl, benzoyl, pivaloyl, trityl, tert- butyldimethylsilyl, benzylidene or isopropylidene.

A second aspect of the invention provides a material (whether a compound or composition) which incorporates a compound of formula I, chemically or physically bound to

a coupling partner such as a label, a supporting substrate, a carrier, an effector or inhibitor molecule or an immobiliser.

In I, suitable protecting groups for R include menthoxycarbonyl (MntCO), an acetal (in particular, two R groups may together represent a bridging acetal such as 0-cyclohexylidene, 0-isopropylidene or 0-benzylidene), tert-butyldimethylsilyl (TBDMS), benzyl (Bn), tert- butyldiphenylsilyl (TBDPS), etc... Many protecting groups suitable for use in the syntheses and reactions of saccharides are known and are well documented in standard reference works. The choice depends in part on the route by which the compound I is synthesised and/or on the uses to which it is to be put, including perhaps on reactions which it is subsequently intended to undergo.

Either or preferably both of Rla and R6f are phosphate. R1a and R2a may together represent a cyclic phosphate group.

X is preferably H3+. Y is preferably AcH.

Preferred forms of compound I are those which are at least partially deprotected, i. e. in which one or more of the R groups is hydrogen. For instance, at least the R groups in units a and b, more preferably units a, b and c, most preferably units a, b, c and d, are either hydrogen or phosphate (e. g. Rla is still preferably phosphate).

A particularly preferred form of compound I is that shown as formula 1 in Figure 1, in which all R groups are hydrogen, with the exception of Rla and R6f which are phosphate, X is H3+ and Y is AcH.

Preferred protected forms of I are those which have been

or could have been prepared by the synthetic methods also provided by this invention (see below). These methods place certain limitations on the nature of the protecting groups R, to ensure the correct stereochemistry of the glycosidic linkages in I, namely: (a) R2C, R2e and R2f are preferably permanent, non- participating protecting groups ; and (b) R1a and R6f are preferably temporary protecting groups chosen to permit orthogonal deprotection with respect to all the permanent protecting groups in I.

In addition, NX is preferably a non-participating group, whereas NY is preferably participating.

A participating group is one which participates in a glycosylation reaction and influences the stereochemistry of thq ? glycosidic linkage formed, leading to a 1,2-trans linkage. A non-participating group is one which in principle does not influence the stereochemical outcome of a glycosylation reaction.

Preferred protecting groups for I include N2 for X, Pht for Y and bridging acetals for the pairs R2a and R3a, RI a and R5a R4d and R6d, R3e and RI and R3f and R.

A particularly preferred protected form of I is that in which Rla is MntCO; R and R3a together represent O- cyclohexylidene, as do R4a and R5a together ; R, R, R R4, R3d, R2e and R2f are benzyl (Bn); RI and R6d together represent 0-benzylidene R3e and R4e, and also R3f and R4f, together represent 0-isopropylidene ; and R"is acetate.

In some embodiments, the compounds and derivatives of the invention are be useful as IPG agonists, and more preferably A-type IPG agonists, sharing one or more of

the biological properties of A-type IPGs. In other embodiments, the compounds and derivatives of the invention may act as IPG antagonists, and more preferably A-type IPG antagonists, e. g. by competing with the IPGs and so reducing one or more IPG biological activities.

A-type mediators modulate the activity of a number of insulin-dependent enzymes such as cAMP dependent protein kinase (inhibits), adenylate cyclase (inhibits) and cAMP phospho-diesterases (stimulates). In contrast, P-type mediators modulate the activity of insulin-dependent enzymes such as pyruvate dehydrogenase phosphatase (stimulates) and glycogen synthase phosphatase (stimulates). The A-type mediators mimic the lipogenic activity of insulin on adipocytes, whereas the P-type mediators mimic the glycogenic activity of insulin on muscle. Both A-and P-type mediators are mitogenic when added to fibroblasts in serum free media. The ability of the mediators to stimulate fibroblast proliferation is enhanced if the cells are transfected with the EGF- receptor. A-type mediators can stimulate cell proliferation in the chick cochleovestibular ganglia.

Soluble IPG fractions having A-type and P-type activity have been obtained from a variety of animal tissues including rat tissues (liver, kidney, muscle brain, adipose, heart) and bovine liver. A-and P-type IPG biological activity has also been detected in human liver and placenta, malaria parasitized RBC and mycobacteria.

The ability of an anti-inositolglycan antibody to inhibit insulin action on human placental cytotrophoblasts and BC3H1 myocytes or bovine-derived IPG action on rat diaphragm and chick cochleovestibular ganglia suggests cross-species conservation of many structural features.

However, it is important to note that although the prior

art includes these reports of A-and P-type IPG activity in some biological fractions, the purification or characterisation of the agents responsible for the activity is not disclosed.

A-type substances are cyclitol-containing carbohydrates, also containing Zon2+ ion and optionally phosphate and having the properties of regulating lipogenic activity and inhibiting cAMP dependent protein kinase. They may also inhibit adenylate cyclase, be mitogenic when added to EGF-transfected fibroblasts in serum free medium, and stimulate lipogenesis in adipocytes.

P-type substances are cyclitol-containing carbohydrates, also containing Mn"and/or Zn"ions and optionally phosphate and having the properties of regulating glycog, en metabolism and activating pyruvate dehydrogenase phosphatase. They may also stimulate the activity of glycogen synthase phosphatase, be mitogenic when added to fibroblasts in serum free medium, and stimulate pyruvate dehydrogenase phosphatase.

Methods for obtaining A-type and P-type IPGs are set out in W098/11116 and W098/11117.

Pharmaceutical Compositions A third aspect of the invention provides a composition comprising a compound, derivative or material according to the first or second aspect (be they an IPG agonist or antagonist), a pharmaceutically acceptable derivative thereof.

The pharmaceutical composition may include other pharmaceutically acceptable adjuvants such as carriers, buffers, stabilisers or other excipients, depending on

the purpose of the composition and its intended route of administration (e. g. oral, intravenous or whatever). It may additionally include other pharmaceutically active ingredients, which may be therapeutically (including prophylactically) active or have some diagnostic function. It may for instance contain insulin, a P-type IPG or IPG analogue, another A-type IPG or analogue, and/or an IPG antagonist. The composition may also, of course, contain more than one compound, derivative or material according to the first or second aspect of the invention.

The composition may be in any suitable form, such as a tablet, capsule, powder or liquid for oral administration, or a solution or suspension for use for instance as a vaccine. Conventional solid or liquid carriers may be used in such formulations. The concentration of the compound, derivative or material contained in the pharmaceutical composition will depend, of course, on the nature and severity of the condition to be treated or diagnosed using the composition, and on the patient to whom and method by which it is to be administered.

Possible uses for the pharmaceutical composition of this third aspect of the invention (which include both therapeutic and diagnostic uses) are described below.

Uses of the Compounds and Compositions In preferred embodiment, the compounds of formula I are expected to mimic, at least to an extent, the biological activity of A-type IPGs, they are equally expected to be of use in therapeutic and diagnostic methods based on that activity. Thus, fourth-sixth aspects of the invention provide, respectively, a compound or derivative

according to the first aspect, or a material according to the second aspect, or an antagonist thereto, for use in any surgical, therapeutic or diagnostic method; the use of such a compound, derivative, material or antagonist in the manufacture of a medicament for use in any surgical, therapeutic or diagnostic method; and a method of surgery, therapy or diagnosis which involves the use of such a compound, derivative, material or antagonist.

The term"therapy"as used here includes prophylaxis.

Moreover, in this section"compound"should be taken to include derivatives, materials and antagonists as referred to in connection with the third aspect of the invention.

The compounds are in particular likely to be of use in treating and/or diagnosing any condition which is related to (ie, which is or can be caused or mediated, directly or indirectly, by, or which is in any way associated with) insulin activity, in particular the effects of the IPG second messengers. They may be used, for instance, in the treatment and/or diagnosis of disorders in which the lipogenic response of a patient has in some way been affected so that he or she produces a relatively low amount of A-type IPGs in response to growth factors such as insulin.

More particularly, the compounds are likely to be of use in the treatment and/or diagnosis of diabetes, including diabetes due to insulin resistance, insulin resistance in type I diabetes and brittle diabetes, and of conditions associated with insulin resistance or insulin underproduction, such as neurotrophic disorders or polycystic ovary disease.

The use of both P-and A-type IPGs in the diagnosis and treatment of diabetes is disclosed in W098/11435. This application discloses that in some forms of diabetes the ratio of P: A-type IPGs is imbalanced and can be corrected by administering a medicament containing an appropriate ratio of P-or A-type IPGs or antagonist (s) thereof. In particular, it describes the treatment of obese type II diabetes (NIDDM) patients with a P-type IPG and/or an A- type IPG antagonist and the treatment of IDDM or lean type II diabetes (body mass index < 27) with a mixture of P-and A-type IPGs, typically in a P: A ratio of about 6: 1 for males and 4: 1 for females. The compounds and compositions of the present invention can be employed in such types of treatment.

The compounds of this invention are also likely to be of use in promoting either in vitro or in vivo neuron proliferation. They may thus have applications in the treatment and/or diagnosis of any condition related to neuron proliferation. The neurons may be central (brain and spinal cord) neurons, peripheral (sympathetic, parasympathetic, sensory and enteric) neurons, or motor neurons. Treatments may involve the treatment of damage to the nervous system, of motor neuron disease, of neurodegenerative disorders or of neuropathy. Damage to the nervous system includes the results of trauma, stroke, surgery, infection (e. g. by viral agents), ischemia, metabolic disease, toxic agents, or a combination of these or similar causes. Motor neuron disease includes conditions involving spinal muscular atrophy, paralysis or amyotrophic lateral sclerosis.

Neurodegenerative disorders include Parkinson's disease, Alzheimer's disease, epilepsy, multiple sclerosis, Huntingdon's chorea and Meniere's disease.

A therapeutic treatment method in which the compounds may be used involves the administration to a patient suffering from a relevant condition a therapeutically (which includes prophylactically) effective amount of one of the compounds, preferably in the form of a pharmaceutical composition according to the third aspect of the invention."Effective amount"means an amount sufficient to cause a benefit (which may be prophylactic) to the subject or at least to cause a change in the subject's condition. The actual amount administered to the patient, and the rate and time-course of administration, will depend on the nature of the subject, the nature and severity of the condition, the administration method used, etc.. Appropriate values can be selected by the trained medical practitioner. The compound may be administered alone or in combination with other treatments, either simultaneously or sequentially.

It may be administered by any suitable route, including orally, intravenously, cutaneously, subcutaneously, parenterally, nasally, intramuscularly, intraperitoneally, etc... It may be administered directly to a suitable site or in a manner in which it targets a particular site, such as a certain type of cell -suitable targeting methods are already known.

A diagnostic method according to the invention might involve the use of one of the compounds (which of course includes antagonists), or of a specific binding partner for it, or of a species which competes with it in binding to another specific binding partner, to determine, either qualitatively or quantitatively, the existence of a particular medical condition or change in condition.

Such a method may be carried out either in vitro or in vivo. One or more of the materials used in the method may be appropriately labelled.

A seventh aspect of the present invention provides a method of preparation of a pharmaceutical composition, involving admixing one or more of the compounds with one or more pharmaceutically acceptable adjuvants, and/or with one or more other therapeutically active agents.

Synthesis of the Compounds Further aspects of the present invention relate to the synthesis of compounds of formula I. The preferred strategy allows their preparation from four readily available monosaccharide units, via three intermediate disaccharide"building blocks". These disaccharide intermediates have the general formulae II, III and IV: in which R, X and Y have the same meanings as in formula I, and each L is a leaving group (or"activating group") which activates the anomeric position of the relevant saccharide unit in preparation for a glycosylation reaction with a glycosyl acceptor, or alternatively a leaving group precursor (ie, a group which can be converted into a suitable leaving group). Each L must be chosen to ensure the optimum balance between reactivity at the anomeric position and selectivity in the unit as a whole, depending on the reactions which the unit in question is to undergo.

The constituent saccharide units of compounds II-IV are again labelled a-f, to reflect their correspondence with the units in formula I.

In compound II, position 1 of unit a is ideally differentiated from the other positions of that unit by the choice of appropriate R groups. For instance, Rla may be MntCO and the rest of the unit may be protected as a dicyclohexylidene acetal in which R2a and R3a, and separately R4a and R5a, together represent the bridging group 0-cyclohexylidene. X is preferably N2. R4b is conveniently H, or a removable precursor group such as TBDMS, in preparation for a subsequent glycosylation of II. R3b and R6b may be protecting groups such as Bn.

In compound III, L is preferably trichloroacetimidate (C (NH) CCl3) or a leaving group precursor such as thiophenyl (SPh). SPh is a preferred leaving group precursor because of its stability and its versatility, being readily convertible into a number of suitable leaving groups. R2C needs to be a permanent, non- participating group, preferably Bn. Suitable groups for R3c and R4e include Bn and TBDPS, preferably Bn for R4C and TBDPS for R3C. R3C should preferably differ from R and . In unit d, NY must be a participating group, preferably NPht, and suitable protecting groups R include an acetal bridging group such as benzylidene acetal for positions 4 and 6, and Bn for position 3.

In compound IV, L is preferably trichloroacetimidate or a leaving group precursor such as thiophenyl. The R groups at positions 2,3 and 4 of both units and position 6 of unit f are suitable protecting groups such as Bn, Ac or (ideally for positions 3 and 4 in each unit) a bridging acetal such as 0-isopropylidene. However R2e and R2f must be permanent non-participating protecting groups such as Bn, and R6f must be a temporary protecting group chosen to permit orthogonal deprotection with respect to all permanent protecting groups in the final product I.

Accordingly, the eighth aspect of the present invention provides a method of synthesis of a compound of formula I, which involves the use, and preferably also the preparation, of at least two of the intermediate disaccharide compounds II, III and IV. This method conveniently involves condensing together the at least two disaccharides to form a tetrasaccharide intermediate compound. The hexasaccharide product is preferably synthesised by reacting the tetrasaccharide intermediate with a third disaccharide intermediate, preferably also selected from compounds II, III and IV. The method preferably involves reacting together at least compounds II and III, more preferably all three compounds II, III and IV.

The method optionally includes the removal, after formation of the hexasaccharide, of one or more protecting groups R, and/or their replacement with other groups such as phosphates, for instance to produce the compound 1. Conventional chemical techniques may be used to effect such substituent changes, the nature and sequence of the reaction steps used depending on the nature of the R groups and on the groups with which they are to be replaced.

Preferably, compounds II and III are reacted together first, to form an intermediate tetrasaccharide of the general formula XI:

in which R, X and Y are as defined in connection with compounds II and III, and R-' is preferably hydrogen.

Compound XI is then preferably glycosylated using compound IV as a glycosyl donor, to form compound I.

This last step will involve the selective deprotection of compound XI at R3c to convert it into a glycosyl acceptor.

A ninth aspect of the invention therefore provides a method of synthesis of a compound of formula I, which involves the use, preferably also the preparation, of a tetrasaccharide intermediate of the formula XI and preferably the reaction of that intermediate with a compound of formula IV.

It Compounds II, III and IV are preferably prepared from the monosaccharide"building blocks"represented by the general formulae V-IX: in which R, X, Y and L have the same meanings as in formulae II-IV, the units again bearing letters corresponding to those which they will provide in compounds I-IV (although compound IX provides both units e and f in compound IV).

Compound II is preferably prepared by firstly preparing the myo-inositol building block V and then glycosylating using a D-glucosamine derivative such as VI as a glycosyl

donor. In the myo-inositol building block, position 6 should be free for glycosylation (i. e. R6a should be hydrogen) and position 1 should ideally be differentiated, as explained in connection with compound II. Compound V may be prepared from myo-inositol using a regioselective acylation reaction via a boron-tin exchange reaction The glycosyl donor is preferably a 2-azido-2-deoxy-D- glucopyranosyl, ie, compound VI with X=N2. L is preferably a trichloroacetimidate leaving group, which may be precursed during the synthesis by for instance a thiophenyl group. Such a compound may be prepared, for instance, from a 2-amino-2-deoxy D-glucosamine hydrochloride, via a diazo transfer reaction from trifluoromethanesulphonyl azide <BR> <BR> R3b, Rlb and R6b in the glycosyl donor may be any suitable protecting groups, such as Bn for R3b and R6b and TBDMS (selectively removable) for R4b. Generally speaking, R4b should be different to R3b and R6b, and more preferably R3b and R6b are the same. Bridging acetals are not preferred as protecting groups since their subsequent reductive opening, during the glycosylation reaction, can lead to hydrolysis of acetal protecting groups present on the myo-inositol unit. Since in compound II, R4b should ultimately be H, position 4b should be selectively deprotected following glycosylation of the myo-inositol block.

Compound III is preferably prepared by glycosylating the mannose derivative VII, with the glucosamine derivative VIII. In VII, L is ideally a leaving group precursor such as thiophenyl, which can be converted to a suitable leaving group following glycosylation with VIII. R6C

should ultimately be hydrogen, leaving that position free for glycosylation. Suitable groups for R2C, R3C and R4C include Bn and TBDPS, preferably Bn for R and R4C and TBDPS for R3C. R2C needs to be permanent and non- participating, as in III. R3C and R6C are mutually orthogonal temporary protecting groups chosen to allow deprotection without affecting the remaining groups at positions 1 and 4.

In the glucosamine derivative VIII used as the glycosyl donor, positions 3,4 and 6 must be protected, whilst L must be a suitable leaving group, fluoride being preferred. Suitable protecting groups include an acetal bridging group such as benzylidene acetal for positions 4 and 6, and Bn for position 3. In the synthesis of the compounds, NY must be a participating group such as NPht. if Compound IV is preferably prepared by reacting together a D-galactose-based glycosyl donor and acceptor, both corresponding to formula IX, both of which can be prepared from appropriate D-galactose derivatives such as (3-D-galactopyranose pentaacetate. In compound IX, for the glycosyl donor, L is a suitable leaving group such as trichloroacetimidate and R2e, R3e, R4e and R6e represent suitable protecting groups such as Bn, Ac or (ideally for positions 3 and 4) a bridging acetal such as O- isopropylidene. For the glycosyl acceptor, R6e should be hydrogen ready for glycosylation, whilst positions 2,3 and 4 must be suitably protected such as with Bn or (again conveniently for positions 3 and 4) a bridging acetal such as 0-isopropylidene. L must be a leaving group precursor, preferably a thiophenyl group. One limitation on the substituents is that R2e in both the glycosyl donor and acceptor must be a permanent non- participating group, Bn being preferred for both.

Thus, the methods of the invention can be seen more preferably to involve preparing the intermediate compounds II, III and IV starting from the four monosaccharide units myo-inositol, D-glucosamine, D- mannose and -D-galactose, any of which may be in the form of a derivative such as a pentaacetate in which, for instance, one or more hydroxyl groups have been replaced by suitable protecting groups. The preferred four starting materials are: myo-inositol D-glucosamine D-mannose-D-galactopyranose pentaacetate Accordingly, a tenth aspect of the invention provides a method of synthesis of a compound of formula I, which involves the use of myo-inositol, D-glucosamine, D- mannose and -D-galactose, and/or of suitable derivatives thereof, as the basic monosaccharide starting materials.

P-D-galactopyranose pentaacetate is preferably used in place of -D-galactose itself.

Clearly the protecting groups used during the synthesis must be carefully chosen so as to ensure availability only of the appropriate substituents at any given time.

Suitable groups are referred to above in connection with the compounds II-IX.

The substituents referred to as preferred in compounds V- IX and/or in compounds II-IV are of course also preferred, in the corresponding positions, in the tetrasaccharide intermediate XI and in the final product I.

Many of the intermediate compounds formed during a synthesis according to the invention are believed to be novel compounds. These include compounds 9,10,11,12, 13,18,19,20,24,25,26,27,28,29,30,31,32,33, 35,36,37,38,39,40,41,42,43,44,45,48,49 or 50 referred to in the Example below. In particular, an eleventh aspect of the invention provides a compound of the general formula II, or a salt or other derivative thereof, in which R4b (which is preferably hydrogen, or a protecting group chosen to permit orthogonal deprotection with respect to the other protecting groups present) is different to R3b and preferably also to R6b, and more preferably R3b and R6b are the same as each other but different to R4b.

Twelfth to eighteenth aspects of the invention provide, respectively, compounds of the general formulae III, IV, VI to IX and XI, as defined above, or in each case a salt or other derivative thereof.

A nineteenth aspect of the present invention provides a method of synthesis of a compound of formula II (as defined above), which involves firstly preparing a glycosyl donor, in the form of a 2-azido-2-deoxy-D- glucopyranosyl of formula VI (with X=N2), from a 2-amino- 2-deoxy D-glucosamine salt via a diazo transfer reaction from trifluoromethanesulphonyl azide (as shown in Figure 4), and then reacting that donor with a glycosyl acceptor in the form of a myo-inositol building block of formula V. The method preferably also involves preparing compound V. The nature of the R and L groups are preferably as described above in connection with the preparation of intermediate II. In particular, R4b is preferably differentiated from the other R groups of the glycosyl donor, so that in the product II position 4b is free for

further glycosylation, for instance for use in the synthesis of the tetrasaccharide XI and/or the hexasaccharide I.

Finally, a twentieth aspect of the invention provides a method of synthesis of a tetrasaccharide of the general formula XI, as defined above, by reacting together a glycosyl acceptor of formula II, in which Rqb is hydrogen, and a glycosyl donor of formula III, in which L is a leaving group. The method preferably also involves preparing one or both of the compounds II and III; more preferably it involves preparing compound II in accordance with the nineteenth aspect of the invention.

Embodiments of the present invention will now be described in more detail by way of example and not limitation with reference to the accompanying drawings.

Brief Description of the Drawings Figure 1 shows the chemical formulae for (1) a preferred hexasaccharide according to the first aspect of the invention and (2) GPI anchors typically present in cell membranes.

Figure 2 shows a retrosynthetic analysis from which the methods of synthesis of the eighth to tenth aspects of the invention were derived; and Figures 3-9 illustrate reaction schemes for a method of synthesis in accordance with the invention.

Examples There is now described an exemplary synthesis, according to the present invention, of a compound of formula I.

The synthesis was devised using the retrosynthetic

analysis depicted in Figure 2. It proceeded via three intermediate disaccharide compounds shown as II, III and IV, which themselves could be prepared (via monosaccharide units V-IX) from the four starting materials myo-inositol, D-glucosamine, D-mannose and ß-D- galactopyranose pentaacetate.

Of note is the choice of protecting groups and leaving groups for the monosaccharide"building blocks"V-IX, to ensure the selective reaction of appropriate substituents during each stage of the synthesis and the desired stereochemistry at each glycosidic link formed.

Preparation of intermediate II Figures 3-5 illustrate the preparation of disaccharide II from myo-inositol and D-glucosamine. A myo-inositol building block 6 was prepared following a previously reported procedure","I that is based on the well established regioselective enhancement of the nucleophilicity of hydroxyl groups as tributyl tin ethers <BR> <BR> <BR> or dibutyl tin acetals"1, but overcoming the insolubility of myo-inositol in most organic solvents by using a boron-tin exchange alsoPotteretal[24](see for background on the preparation of myo-inositol derivatives).

Thus, myo-inositol was converted into the hexane soluble hexa-O-diethylboryl derivative 3 (100% yield), which was reacted in situ with dibutyl tin bis-acetylacetonate and then with L-menthyl chloroformate to give a diastereomeric mixture of regioselectively monosubstituted derivatives 4 and 5, from which the desired diastereoisomer 4 could be separated. 4 was then transformed into the building block 6, leaving position 6

free for glycosylation and position 1 differentiated, after protection as a dicyclohexylidene acetal.

Cyclohexylidene acetals of myo-inositol have been frequently used as intermediates in the preparation of glycosyl myo-inositols[31, Compound 6 was most conveniently prepared using 1-ethoxycyclohexene for the acetalation reaction, in cyclohexanone under conditions of thermodynamic control.

The 1,2-cis glycosylation of 6 was conveniently carried out using a 2-azido-2-deoxy-D-glucopyranosyl trichloroacetimidate as the glycosyl donor. 2-azido-2- deoxy-glycosyl donors are currently employed in oligosaccharide syntheses but most of the methods used for the preparation of the 2-azido-2-deoxy building blocks involve low diastereoselectivity and a large <BR> <BR> <BR> number of steps''. There is however reported a one- pot synthesis of peracetylated 2-azido-2-deoxy sugars from commercially available 2-amino-2-deoxy sugar hydrochlorides through a diazo transfer reaction from trifluoromethanesulphonyl azide, and this method can be used to prepare the glycosyl donors 15 and 17 as shown in Figure 4.

D-glucosamine hydrochloride was thus converted[37] into the tetra-O-acetylated 2-azido-2-deoxy derivative 8, which in turn was converted into the thioglycoside 91"1 that was then transformed using well established chemical techniques t132339-43] into the trichloroacetimidates 15 and 17, via the intermediates 10-14 and 10,11 and 16, respectively (see"Materials and Methods").

Glycosylation of the myo-inositol building block 6 with

glycosyl donor 17 in the presence of trimethylsilyl triflate in diethyl ether (231 afforded 18 as a 10: 1 otl mixture in 95% yield (Figure 5). The subsequent reductive opening of the benzylidene acetall"I in this mixture, however, resulted in partial hydrolysis of the cyclohexylidene acetals; the donor 15 was therefore preferred for the glycosylation to prepare intermediate compound II.

Thus, 15 was condensed with 6 under the conditions mentioned above, as shown in Figure 5, to give 19 (corresponding to intermediate II) as a 9: 1 a/ mixture in 73% yield. Treatment of 19 with tetrabutyl ammonium fluoride afforded the product 20 (with position 4 of the glucosamine unit deprotected) in 83% yield.

Preparation of intermediate III Referring now to Figure 6, compound III was prepared from the readily available mannose derivative, 1,6-anhydro-ß- D-mannopyranose (21), via the protected mannose unit 29 which was then glycosylated with the glucosamine fluoride derivative 30. Conversion of 20 to 28 was carried out according to the method described in Klooterman et al[36].

Glycosylation of 29 was conveniently performed according to the methodology reported in Suzukil"1, which gave with excellent yield and selectivity the disaccharide 31.

This was then converted [18,19,23] into the trichloroacetimidate 33 (i. e. the intermediate III) via compound 32 (see"Materials and Methods").

Preparation of intermediate IV Figure 7 illustrates the preparation of IV from the galactose derivative P-D-galactopyranose pentaacetate (34). This was converted [21,38,45] to the glycosyl acceptor

35, which was also further converted, via 36 and 37 (see "Materials and Methods"), into the glycosyl donor 38.

The glycosylation reaction of 35 and 38 afforded the disaccharide 39 as a 6: 1 a/ mixture in 86% yield. This was further transformedlg-1s, 23 into the trichloroacetimidate 41 via 40 (see"Materials and Methods"). 41 corresponds to intermediate IV.

Combination of II, III and IV Figure 8 shows the preparation of the hexasaccharide product 44 corresponding to compound I. Firstly, disaccharides 20 (intermediate II) and 32 (intermediate III) were condensed together to give the tetrasaccharide 42, with excellent stereoselectivity and an 81% yield. A carefully controlled desilylation of 42 led with a good yield to the glycosyl acceptor 43 (corresponding to XI), which carries a hydroxyl group at position 3 of the D- mannose unit.

43 was then glycosylated with the trichloroacetimidate 41 (intermediate IV) to give the hexasaccharide 44 as a 6.5: 1 a/ (3 mixture in 83% yield.

Deprotection of 44 To reach the compound 1 from 44, conventional methods may be used to remove each of the protecting groups. As an example, firstly Rla might be removed using an excess of LiOH in THF/MrOH at room temperature. This would simultaneously remove the acetate group R, and also cause partial opening of the phthalimido group in unit d.

The phthalimido group could be cyclised again by treatment with Et3N/Ac2O, which would lead to acetylation of both Rla and R6f. The phthalimido group could then be

removed, for instance using a large excess of ethylenediamine in n-butanol at 90°C, with subsequent acetylation of the resulting amine under the usual conditions. O-deacetylation would then give a diol (i. e.

Rla and R6f being H) which could be subjected to phosphorylation using the phosphoramidite procedure.

Finally, treatment with hydrogen in the presence of 10% Pd/C would yield the final deprotected product 1.

Materials and Methods General Remarks: TLC was performed on precoated plates (Merck aluminium sheets silica 60 F254, Art. no. 5554); detection was effected by observation under UV light (254 nm), then visualised using sulfuric acid or phosphomolybdic acid in EtOH followed by heating. Column chromatography was conducted with Silica Gel 60 (0. 023- 0.040fnm, E. Merck) using de flash procedure. Melting points were determined using a Reicher Jung Thermovar apparatus and are uncorrected. Specific rotations were measured on a Perkin Elmer model 241 polarimeter. NMR spectra were recorded on Bruker AMX-200, Avance DRX-500, Varian Gemini-200, XL-300 or Unity 500 spectrometers.

Chemical shifts are expressed in ppm and referred to the residual signal of the solvent used. Microanalysis was carried out by the Analysis Department of the Instituto de Quimica Organica General (CSIC) on a Heraus CHNO-Rapid apparatus.

2,3: 4,5-Di-O-cyclohexylidene-1-O-(-)-menthoxycarbonyl-lD- myo-inositol (6) and 2,3: 5,6-di-O-cyclohexylidene-1-O-(- )-menthoxycarbonyl-1-D-myo-inositol (7). To a solution of 100 mg (0.276 mmol) of 1-0- (-) menthoxycarbonyl-myo- inositol 1261 (4) and 5.7 mg (0.03 mmol) of dried p-TsOH in 2 mL of cyclohexanone at room temperature was added 350 mL (2.76 mmol) of 1-ethoxycyclohexene. The reaction

mixture was stirred for 3 h 30 min, quenched with Et3N and evaporated. Silica-gel column chromatography (hexane- EtOAc, 5: 1) afforded 73 mg (50%) of 6 and 41 mg (28%) of 7. Compound 6: White solid. Rf (hexane-EtOAc, 4: 1) = 0.26. Mp: 83-85°C. [α]D-50. 4 (c 1.0, CHCl3). 1H NMR (CDCl3, 200 MHz) d: 0.76 (d, 3H, CH3 Mnt), 0.88 (d, 3H, CH3 Mnt), 0.92 (d, 3H, CH3 Mnt), 1.00-1.13 (m, 1H, Mnt), 1.37- 1.76 (m, 22H, 16H cyclohex, 6H Mnt), 1.92-2.00 (m, 1H, Mnt), (m, 1H, Mnt), 2.70 (d, 1H, JOH,6 = 3.5 Hz, 1H, OH), 3.44 (dd, J5, = 10.5 Hz, L7,, 6 = 9.0 Hz, 1H, H5), 3. 85 (dd, J4, 5 = 10. 5 Hz, J4, 3 = 7.9 Hz, 1H, H4), 4.10- 4.14 (m, 1H, H6), 4.33 (dd, J3, 2 = 6.2 Hz, J3, = 7.9 Hz, 1H, H3), 4.54 (dt, 1H, Ment), 4.60 (dd, J2, 1 = 4.5 Hz, J2, 3 = 6,1 Hz, 1H, H2), 4.79 (t, Jl 2 = J1 6 = 4.6 Hz, 1H, H1). 13C NMR (CDCl3, 50 MHz) d: 16.6,21.2,22.4,23.7,24.0,24.1, 24.3,25.4,25.5,26.5,31.9,32.1,34.5,35.0,36.9, 37.0,37.2,41.1,47.4,72.5,73.7,76.6,78.3,79.1, 79.6,111.6,113.3,154.3. Compound 7: Colourless oil.

Rf: 0.14 (hexane/EtOAc 4: 1). 1H NMR (CDCl3, 200 MHz): d 0.77 (d, 3H, CH3 Mnt), 0.88 (d, 3H, CH3 Ment), 0.91 (d, 3H, CH3 Mnt), 1.00-1.15 (m, 1H, Mnt), 1.37-1.69 (m, 26H, 20H cyclohexylidene, 6H Mnt), 1.93-2.09 (m, 2H, Mnt), 2.95 (bs, 1H, OH), 3.40 (t, J5, 5, 6= 10.1 Hz, 1H, Hs), 3.88 (dd broad, J4, 5 = 10.6 Hz, J4,3 = 6.5 Hz, 1H, H4), 4.01-4.13 (m, 2H, H6, H3), 4.58 (dt, 1H, Mnt), 4.70 (t, J2,3=4.7Hz,1H,H2),4.89(dd,J1,2=4.4Hz,J1,6=J2,1= 10.5 Hz, 1H, Hl). 13 C NMR (CDCl3, 50 MHz): d 16.8 (-), 21.1 (-), 22.4 (-), 23.9 (+), 24.0 (+), 24.4 (+), 25.4 (+), 26.7 (-), 31.9 (-), 34.5 (+), 35.2 (+), 36.8 (+), 36.9 (+), 38.2 (+), 41.2 (+), 47.6 (-), 74.5 (-), 74.6 (-), 74.7 (-), 75.3 (-), 78.4 (-), 79.3 (-), 81.8 (-), 111.4 (o), 114.0 (o), 154.5 (o).

Phenyl 3,4,6-tri-O-acetyl-2-azido-2-deoxy-1-thio-D-

glucopyranoside (9). To a solution of 2.10 g (5.63 mmol) of 1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-D- glucopyranose' in 45 mL of CH2Cl2 at room temperature was added 1.15 mL (11.25 mmol) of thiophenol and 3.12 mL (25.31 mmol) of boron trifluoride diethyl etherate. The reaction mixture was stirred for 8 days, diluted with CH2Cl2, washed with NaCl and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 1.58 g of 9 (66%), as a 3: 1 a/ (3 mixture, and 0.53 g of recovered 8 (25%). Rf (hexane-EtOAc, 3: 1) = 0.27. 1H NMR for 9a, taken from the spectra of the jazz mixture, (200 MHz, CDCl3) d: 1.96 (s, 3H, CH3CO), 1.99 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO), 3.96 (dd, Jazz 6b = 12. 4 Hz, J6a 5 = 2. 2 Hz, 1H, H6a), 4.02 (dd,, 3 = 10.6 Hz, J2 1 = 5.7 Hz, 1H, H2), 4.23 (dd, J6b, 6a = 12.4 Hz, Job 5 = 5.1 Hz, 1H, H6b), 4.53 (ddd, J5, 4 = 10.2 Hz, J5,6b = 5.1 Hz, L75, sa = 2. 2 Hz, 1H, H5), 4.96 (+t, J4 3 = J4,5 = 10. 1 Hz, 1H, H4), 5.27 (dd, L73, 2 = 10.4 Hz, J3,4 = 9. 8 Hz, 1H, H3), 5.58 (d, J1 2 = 5. 7 Hz, 1H, H1), 7., 20-7. 45 (m, 5H, ArH). 1H NMR for 9ß, taken from the spectra of the a/ (3 mixture, (200 MHz, CDCl3) d: 1.94 (s, 3H, CH3CO), 1.97 (s, 3H, CH3CO), 2.02 (s, 3H, CH3CO), 3-34 (t, J2 3 = J2,1 = 10.1 Hz, 1H, H2), 3.63 (ddd, L75, 4 = 9.8 Hz, J5, 6b = 4.9 Hz, Js 6a = 2.6 Hz, 1H, H5), 3.92-4.21 (m, 2H, H6a, H6b), 4.42 (d, J1,2 = 10.1 Hz, 1H, H1), 4. 86 (t, J4,5=9.7Hz,1H,H4),5.01(t,J3,2=J3,4=9.7= Hz, 1H, H3), 7.20-7.45 (m, 5H, ArH).

Phenyl 2-azido 4,6-O-benzylidene-2-deoxy-1-thio-D- glucopyranoside (10). To a solution of 3.00 g (7.09 mmol) of 9 in 110 mL of MeOH at room temperature was added 5 mL of sodium methoxide in MeOH (0.3M). After 20 min, the solution was neutralized with Amberlite IR-120, filtered and evaporated. The crude mixture of phenyl 2- azido-2-deoxy-1-thio-D-glucopyranosides obtained was

dissolved in 30 mL of CH3CN. 5.32 mL (35.45 mmol) of benzaldehyde dimethyl acetal and 67.4 mg (0.35 mmol) of p-toluensulfonic acid were added and the reaction mixture was stirred for 2 h at rt, quenched with Et3N and evaporated. Silica-gel column chromatography (hexane- EtOAc, 6: 1) afforded 1.85 g of 10a and 0.80 g of 10ß (7: 3 <BR> <BR> <BR> <BR> ratio, 97% total yield). Data for 10a.: white solid. Rf (hexane-EtOAc, 3: 1) = 0.34. Mp: 127-128°C. [a] m+ 226.9 (c 1. 09, CHC13). 1H NMR (200 MHz, CDCl3) d: 2.90 (d, Jon, 3 = 2.0 Hz, 1H, OH), 3. 58 (t, J4, 3 = J4,5 = 9.3 Hz, 1H, H4), <BR> <BR> <BR> 3. 76 (t, Jea, 5 = J6a, 6b = 10. 2 Hz, 1H, H6a), 3.92 (dd, J2, 3 =<BR> <BR> <BR> <BR> <BR> 9.8 Hz, J2 1 = 5.4 Hz, 1H, H,), 4.07 (dt, J3,4 = J3,2 = 9. 6 Hz, J3, oH- 2.0 Hz, 1H, H3), 4.24 (dd, J6b, 6a = 10. 2 Hz, J6b, s- <BR> <BR> <BR> 4.9 Hz, 1H, H6b), 4.41 (dt, J5, 4 = Js, 6a = 10. 2 Hz, J5,6b = 4. 9 Hz, 1H, H5) 1 5.57 (s, 1H, H,), 5.58 (d, J1 2 = 5.4 Hz, 1H, H1), 7.30-7.56 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d: 63.46,63.91,68.51,70.72,81.68,87.81,102.18,126.19, 126.29,128.01,128.40,129.18,129.42,132.47,133.05, 136.80. Anal. Calcd. for C1gHlgN304S: C, 59.21; H, 4.97; N, 10.90; S, 8.32. Found: C, 59.13; H, 5.08; N, 10.71; S, 8.13. Data for 10ß: white solid. Rf (hexane-EtOAc, 3: 1) <BR> <BR> <BR> = 0.36. Mp: 152-154°C. [a] o-65.8 (c 0.96, CHCl3). 1H<BR> <BR> <BR> <BR> <BR> NMR (200 MHz, CDCl3) d: 2. 88 (d, JoH, 3 = 2. 1 Hz, 1H, OH), 3.35 (dd, J2,1 = 10.2, J2, 3 = 9.0 Hz, 1H, H2), 3.41-3.52 (m, 2H, H4, H5), 3.73 (dt, J3, 2 = J3,4 = 8.9 Hz, J3, oH= 2. 1 Hz, 1H, H3), 3.77 (t, Jasa, 6b = J6a,5 = 10.2 Hz, 1H, H6a), 4.38 <BR> <BR> <BR> (dd, J6b, 6a = 10. 2 Hz, J6b, 5 = 4.4 Hz, 1H, H6b), 4. 52 (d, J1 2 = 10.2 Hz, 1H, H1), 5.53 (s, 1H, H7), 7.35-7.61 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d: 65.20,68.41,70.27, 67, 129.12,129.41,130.88,133.67,136.74. Anal. Calcd. for <BR> <BR> <BR> ClgHlgN304S: C, 59.21; H, 4.97; N, 10.90; S, 8.32. Found: C, 59.09; H, 4.65; N, 10.81.

Phenyl 2-azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-1- thio-D-glucopyranoside (11). To a solution of 546 mg (1.42 mmol) of 10ß in 9 mL of DMF at room temperature was added 43 mg (1.70 mmol) of sodium hydride and then 0.21 mL (2.84 mmol) of benzyl bromide. The reaction mixture was stirred for 40 min, quenched with a saturated aqueous solution of NaHCO3 and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc) afforded llß in 98% yield. Following the same procedure, lla was synthesized using 10α as starting material in 95% yield. Data for 11ß : white solid. Rf (hexane-EtOAc, 3: 1) = 0.58. Mp: 106- 108°C. [α]D - 121. 0 (c 0.93, CHC13). lH NMR (200 MHz, CDCl3) d: 3.38 (dd, J2,1 = 10.2, J2, 3 = 9.1 Hz, 1H, H2), 3.45 (m, 1H, H5), 3.60 - 3. 69 (m, 2H, H3, H4), 3.81 (t, <BR> <BR> <BR> <BR> J6a,6b = J6a,5 = 10. 2 Hz, 1H, H6a), 4.41 (dd, J6b, 6a = 10.2 Hz, J6b, 5 = 4. 9 Hz, 1H, H6b), 4.51 (d, J1, = 10.2 Hz, 1H, H,), 4.87 ('dd, 2H, CH2Ph), 5.59 (s, 1H, H), 7.31-7.61 (m, 15H, ArH). 13C NMR (50 MHz, CDCl3) d: 64.75,68.50,70.50, 75.19,, 80.97,81.31,86.67,101.29,125.97,128.00, 128.30,128.42,128.72,129.11,133.92,137.09,137.58.

Anal. Calcd. for C26H25N30, S: C, 65.67; H, 5.30; N, 8.84; S, 6.74. Found: C, 65.91 H, 5.21; N, 8.52; S, 6.58. Data for lla: white solid. Rf (hexane-EtOAc, 3: 1) = 0.54. Mp: 145- 147°C. [a], + 125.6 (c 0.74, CHC13). lH NMR (200 MHz, CDCl3) d: 3.73-3. 83 (m, 1H, H4), 3.78 (t, J6a, 6b = J6a, s = 10.3 Hz, 1H, H6a), 3.92-4.04 (m, 2H, H2, H3), 4.24 (dd, J6b, 6a = 10.3 Hz, J6b, 5 5. 0 Hz, 1H, H6b), 4.44 (dt, J5, 4 = Js, 6a = 10.3 Hz, J5, 6b 5. 0 Hz, 1H, H5), 4. 92 (dd, 2H, CH2Ph), 5.58 (m, 1H, H1), 5.62 (s, 1H, H7), 7.30-7.53 (m, 15H, ArH). 13C NMR (50 MHz, CDCl3) d: 84, 82,82.74,87.90,101.51,126.01, 42,129.09,129.17,132.47, 133.01,137.12,137.67. Anal. Calcd. for C26H25N304S: C, 65.67; H, 5.30; N, 8.84; S, 6.74. Found: C, 65.50; H,

5.12; N, 8.68; S, 6.42.

Phenyl 2-azido-3,6-di-O-benzyl-2-deoxy-1-thio-D- glucopyranoside (12). A solution of 447 mg (0.94 mmol) of 11ß in 9.4 mL of THF containing 3Å molecular sieves was stirred for 30 min at room temperature; after this, 1.201 g (18.16 mmol) of sodium cyanoborohydride was added. A saturated solution of hydrogen chloride in diethyl ether was then added dropwise until the evolution of gas had ceased (pH < 7) and a TLC analysis showed conversion of all the starting material. The mixture was neutralized with a saturated aqueous solution of NaHCO3, diluted with CH2Cl2, filtered through celite, washed with water and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 430 mg of 12 (96%) as a colourless oil. Following the same procedure, 12a was synthesized using lla as starting material in 87% <BR> <BR> <BR> <BR> <BR> yield. Data for 12: Rf (hexane-EtOAc, 3: 1) = 0.28. [α]D -64.2 (c 1.10, CHCl3). 1H NMR (200 MHz, CDCl3) d: 2.70 (d, Joui, 4 = 2.4 Hz, 1H, OH), 3.27-3.41 (m (ABX), 2H, H2, H3), 3.47 (m, 1H, Ho), 3.65 (dt, J4, 3 = J, 5 = 8.5 Hz, J4.0H = 1H,H4),3.75(dd,J6a,6b=10.42.4Hz, Hz, 4.3Hz,= 1H, H6a), 3. 81 (dd, J6b,6a = 10.4 Hz, J6b 5 = 4.9 Hz, 1H, H6b), 4.45 (m (ABX), J12 = 9. 9 Hz, 1H, H1), 4.59 (dd, 2H, CH2Ph), 4.87 (dd, 2H, CH2Ph), 7.28-7.61 (m, 15H, ArH).

13C NMR (50 MHz, CDCl3) d: 64.55,70.27,71.88,73.72, 75.42,78.05,84.60,86.23,127.66,127.82,128.08, 33,128.45,128.59,128.96,131.29,133.48, 137.71,137.86. Anal. Calcd. for C26H27N3O4S : C, 65.39; H, 5.70; N, 8.80; S, 6.71. Found: C, 65.61; H, 5.35; N, 8.58; S, 6.35. Data for 12a. Rf (hexane-EtOAc, 3: 1) = <BR> <BR> <BR> <BR> <BR> 0.31. [a], + 124.9 (c 1.34, CHCl3). 1H NMR (200 MHz, CDCl3) d: 2. 51 (d, JoH, 4 = 2.7 Hz, 1H, OH), 3.62-3.75 (m, 3H, H3, H6ar H6b) 3. 77 (dt, , J4 3 = J,, 5 = 8.0 Hz, JoH= 2.7 Hz,

1H, H4), 3.92 (dd, J2,3 = 10.0 Hz, J2, 1 = 5. 4 Hz, 1H, H2), 4.35 (m, 1H, Hs) 4.56 (dd, 2H, CH2Ph), 4.91 (dd, 2H, CH2Ph), 5.58 (d, J2i 1 = 5.4 Hz, 1H, H1), 7.25-7.54 (m, 15H, ArH). 13C NMR (50 MHz, CDCl3) d: 63.59,69.72,71.05, 72.36,73.63,75.39,81.32,87.28,127.68,127.80, 128.11,128.17,128.43,128.65,129.05,132.16,133.43, 137.71,137.95. Anal. Calcd. for C26H27N304S: C, 65.39; H, 5.70; N, 8.80; S, 6.71. Found: C, 65.74; H, 6.05; N, 8.81; S, 6.60.

Phenyl 2-azido-3,6-di-O-benzyl-4-O-(tert- butyldimethylsilyl)-2-deoxy-1-thio-D-glucopyranosi-de (13). A solution of 345 mg (0.72 mmol) of 12ß and 287 mL (2.17 mmol) of collidine in 1 mL of CH2C12 was cooled at 0°C. 249 mL (1.08 mmol) of tert-butyldimethylsilyl triflate were added dropwise during 2 h. The mixture was stirred for 10 min and quenched with water/ice, diluted and extracted with CH2Cl2, washed with brine and dried over Na2SO4. Silica-gel column chromatography afforded 405 mg of 13p (95%) as a colorless oil. 13a was synthesized similarly using 12a as starting material in 98% yield. Data for 13 : Rf (hexane-EtOAc, 5: 1) = <BR> <BR> <BR> 0.69. [a] D-0.2 (c 0.65, CHCl3). 1H NMR (200 MHz, CDCl3) d: 0.01 (s, 3H, CH3), 0.03 (s, 3H, CH3), 0.88 (s, 9H, tBu), 3.24-3.40 (m (ABX), 2H, H2, H3), 3.45 (m, 1H, H5), <BR> <BR> <BR> 3.57-3.68 (m, 1H, H4), 3.64 (dd, J6a, 6b = 10.7 Hz, J6a, s =<BR> <BR> <BR> <BR> 5.4 Hz, 1H, H6a), 3. 78 (dd, J6b,6a = 10.7 Hz, J6b,5 = 2.1 Hz,<BR> <BR> <BR> <BR> <BR> 1H, H6b), 4.50 (m (ABX), jl, 2 = 9.7 Hz, 1H, H1), 4. 59 (dd, 2H, CH2Ph), 4.84 (dd, 2H, CH2Ph), 7.20-7.66 (m, 15H, ArH)."C NMR (50 MHz, CDCl3) d:-4.74,-3.78,17.98, 25.91,65.74,69.12,70.55,73.37,75.57,80.70,85.48, 86.49,127.51,127.59,128.11,128.33,128.97,131.71, 133.71,137.98,138.37. Anal. Calcd. for C32H4lN304SSi: C, 64.94; H, 6.98; N, 7.10; S, 5.42. Found: C, 65.45; H,

7.00; N, 6.96; S, 5.32. Data for 13a: Rf (hexane-EtOAc,<BR> <BR> <BR> <BR> <BR> 5: 1) = 0.62. [a] D + 160.0 (c 1.38, CHCl3). 1H NMR (200 MHz, CDCl3) d: 0.02 (s, 3H, CH3), 0.05 (s, 3H, CH3), 0. 90 (s, 9H, tBu), 3.58 (dd, J3,2 = 10.1 Hz, J3,4 = 8.4 Hz, 1H, H3), 3.71 (bd, J = 3.8 Hz, 2H, H6a, H6b) 3. 74 (Yt, J4 3 = 8.4 Hz, J4, 5 = 9.4 Hz, 1H, H4), 3.95 (dd, J2, 3 = 10. 1 Hz, J2,1 = 5. 4 Hz, 1H, H2, 4.37 (dt, J5, 4 = 9. 4 Hz, Js 6a su = 3.8 Hz, 1H, H5), 4.55 (dd, 2H, CH2Ph), 4.87 (dd, 2H, CH2Ph), 5.63 (d, J1, 2 = 5.4 Hz, 1H, H1), 7.21-7.61 (m, 15H, ArH). 13C NMR (50 MHz, CDCl3 d:-4.75,-3.71,18.03, 25.94,64.78,68.91,71.29,73.13,73.17,75.20,81.84, 87.41,127.30,127.47,127.70,128.27,129.01,132.44, 133.62,138.06,138.15. Anal. Calcd. for C32H4lN304SSi: C, 64.94; H, 6.98; N, 7.10; S, 5.42. Found: C, 65.26; H, 6.77; N, 7.20; S, 5.50.

2-Azido-3,6-di-O-benzyl-4-O- (tert-butyldimethylsilyl)-2- deoxy-D-glucopyranose (14). A solution of 331 mg (0.56 <BR> <BR> <BR> mmol) of 13p in 12 mL of acetone was cooled to-15 °C in darkness and 129 mg (0.73 mmol) of NBS were added. After 45 min, the reaction mixture was quenched with a saturated aqueous solution of NaHCO3, diluted and extracted with EtOAc, washed with brine and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 7: 1) afforded 279 mg of 14, as a 11: 1 ol/ß mixture of anomers (quantitative yield). The same procedure was used for 13a to afford 14 in 91% yield. Rf (hexane-EtOAc, 6: 1) = 0.15. M. p. : 76-78°C. lH NMR for 14a (200 MHz, CDCl3) d:-0.04 (s, 3H, CH3), -O. 03 (s, 3H, CH3), 0.84 (s, 9H, tBu), 3.35 (dd, J2. 3 = 10.1 Hz, J2 1 = 3.5 Hz, 1H, H2), 3.49 (dd, J6a, 6b = 10.1 Hz, J6a,5 = 6@ 9 Hz, 1H, H6a), 3.54 (dd, J4 3 = 8.5 Hz, J4,5 = 9.7 Hz, 1H, H4), 3.69 (dd, Jazz 6a = 10.1 Hz, J6b, 5 = 2. 1 Hz, 1H, H6b), 3.81 (dd, J3, 2 = 10.1 Hz, J3,, = 8.5 Hz, 1H, H3), 4.04-4.14 (m, 1H, Hs), 4.59 (dd,

2H, CH2Ph), 4.84 (dd, 2H, CH2Ph), 5.37 (bd, J = 3. 2 Hz, 1H, H1), 7.28-7.41 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d:-4.81,-4.74,-3.75,17.93,25.85,64.45,67.78, 69.25,71.16,71.65,71.83,73.34,73.47,74.99,76.07, 77.18,80.11,83.10,92.05,96.30,127.38,127.44, 127.66,127.77,127.91,128.22,128.42,137.71,138.15.

Anal. Calcd. for C26H37N3OsSi: C, 62.50; H, 7.46; N, 8.41.

Found: C, 62.80; H, 7.08; N, 8.15.

2-Azido-3,6-di-O-benzyl-4-O-(tert-butyldimethylsilyl)-2- deoxy-D-glucopyranosyl trichloraceti-midate (15). To a solution of 241 mg (0.48 mmol) of 14 in 2.5 mL of CH2Cl2 at room temperature, were added 484 mL (4.83 mmol) of trichloracetonitrile and 67 mg (0.48 mmol) of flame dried potassium carbonate. After 1 h 45 min, the reaction mixture was diluted with CH2Cl2, filtered through celite and evaporated at reduced pressure. Silica-gel column chromatography (hexane-EtOAc, 10: 1) afforded 198 mg of 15a and 85 mg of 15 (7: 3 ratio, 91% total yield). Data <BR> <BR> <BR> <BR> for 15ß. Rf (hexane-EtOAc, 6: 1) = 0.43. [a] D + 28.5 (c 2.10, CDCl3). 1H NMR (200 MHz, CDCl3) d: 0.07 (s, 3H, CH3), 0.09 (s, 3H, CH3), 0.87 (s, 9H, tBu), 3.35 (dd, J = 9.6 Hz, J = 8.4 Hz, 1H, H40, 3.54-3.83 (m, 4H, H3, H5, Hua, H6b), 3. 69 (dd, J2,3 = 10.6 Hz, J2,1 = 8.3 Hz, 1H, H2), 4.59 (dd, 2H, CH2Ph), 4.86 (dd, 2H, CH2Ph), 5.71 (d, J1,2 = 8. 3 Hz, 1H, H1), 7.28-7. 40 (m, 10H, ArH), 8.80 (s, 1H, NH).

13C NMR (50 MHz, CDCl3) d:-4.82,-3.83,18.00,25.92, 66.13,68.27,70.28,73.23,75.07,77.64,83.42,96.95, 127.36,127.47,127.54,128.30,138.15,138.34,161.01. <BR> <BR> <BR> <BR> <P>Data for 15a. Rf (hexane-EtOAc, 6: 1) = 0.38. [α]D + 94. 7 (c 1.38, CDCl3). 1H NMR (200 MHz, CDCl3) d: 0.06 (s, 3H, CH3), 0. 08 (s, 3H, CH3), 0.90 (s, 9H, tBu), 3.65-3.95 (m, 6H, H2, H3, H4, H5, H6a, H6b), 4. 57 (dd, 2H, CH2Ph), 4.89 (dd, 2H, CH2Ph), 6.50 (d, Jl, 2 = 3.4 Hz, 1H, H1), 7.32-

7.41 (m, 10H, ArH), 8.75 (s, 1H, NH). 13C NMR (50 MHz, CDCl3) d:-4.83,-3.76,18.00,25.94,63.68,68.24,70.48, 73.26,74.90,75.07,80.38,94.98,127.34,127.48, 128.22,128.26,137.90,138.12,160.81. Anal. Calcd. for C26H37Cl3N4O5Si : C, 52.22; H, 5.79; N, 8.70. Found: C, 52.51; H, 5.45; N, 8.48.

2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-D- glucopyranose (16). To a solution of 80 mg (0.168 mmol) of lla in 1.7 mL of acetone cooled at-15 °C in the dark was added 51.5 mg (0.289 mmol) of NBS. After stirring for 1 h 15 min, the reaction mixture was quenched with a saturated aqueous solution of NaHCO3, diluted and extracted with EtOAc, washed with brine and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 2: 1), afforded 62 mg (96%) of 16 as a white solid, mixture of a/ß (1: 1) isomers. Rf (hexane-EtOAc, 2: 1) = 0.41. M. p. : 115-117°C. 1H NMR (CDCl3, 200 MHz) d: 3.08 <BR> <BR> <BR> (bd, JQH, 1 = 3.0 Hz, 1H, OH), 3.31 (dd, J2 1= 7. 7 Hz,2, 3=<BR> <BR> <BR> <BR> 8.8 Hz, 1H, H2b), 3.30-3. 37 (m, 1H, H5b), 3.39 (dd, J2, 1 =<BR> <BR> <BR> <BR> <BR> 3. 7 Hz, J2,3 = 10.0 Hz, 1H, H2a), 3.51 (t, J4 3 = J4 5 = 9.2 Hz, 1H, -3.73(m,4H,H3b,H6b,2Ha),3.98-3.60 4.07 (m, 2H, Ha), 4.20 (dd, J6,5 = 4.9 Hz, Je, 65 = 10.3 Hz, 1H, H6), 4.24 (dd, J6,5 = 5.0 Hz, J6,6, = 10.5 Hz, 1H, H6), 4.50 (bdd, J1, OH = 3.1 Hz, J1, 2 = 7.8 Hz, 1H, Hlb), 4.78 (dd, 2H, CH2Phb), 4.80 (dd, 2H, CH2Pha), 5.16 (bt, J1, 2 = J1, oH = 3.1 Hz, 1H, H1a), 5.49 (s, 1H, H7b), 5.51 (s, 1H, H, J, 7.16 -7.44 (m, 10H, ArH). 13C NMR (CDCl3, 50 MHz) d: 62.7, 63.5,66.3,67.2,68.4,68.9,74.9,75.1,76.2,79.0, 81.4,82.7,92.7 (C-la), 96.4 (C-lb), 101.3 (C-7), 101.4 (C-7), 125.9,126.0,127.9,128.2,128.3,128.4,129.1, 137.0,137.1,137.7.

2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-D-

glucopyranosyl trichloracetimidate (17). To a solution of 177 mg (0.46 mmol) of 16 in 2.5 mL of CH2Cl2 at room temperature, were added 463 mL (4.62 mmol) of trichloracetonitrile and 64 mg (0.46 mmol) of activated potassium carbonate. After 1 h 30 min, the reaction mixture was diluted with CH2Cl2, filtered through celite and evaporated. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 99 mg of 17 and 125 mg of a <BR> <BR> <BR> <BR> 1: 5 mixture of 17a and 17, respectively (92% total<BR> <BR> <BR> <BR> <BR> yield, 1: 10 a/ mixture). Data for 17ß. Rf (hexane-<BR> <BR> <BR> <BR> <BR> EtOAc, 4: 1) = 0.45. [a] D-59.9 (c 0.99, CHCl3). 1H NMR (200 MHz, 3.56-3.89(m,5H,H2,H3,H4,H5,H6,),d: <BR> <BR> <BR> <BR> 4.41 (dd, J6,5 = 4.8 Hz, J6. 6w = 10.5 Hz, 1H, H6), 4.90 (dd, 2H, CH2Ph), 5.60 (s, 1H, H,), 5.70-5.74 (m, 1H, H1), 7.30-7.52 (m, 10H, ArH), 8.77 (s, 1H, NH), 13C NMR (CDCl3, 50 MHz) d: 65.5,66.9,68.3,74.9,79.0,81.1, 96.7 (C-1), 101.4 (C-7), 125.9,127.9,128.1,128.2, 128.3,129.1,136.9,137.6,160.8. Data for 17a. Rf (hexane-EtOAc, 4: 1) = 0. 36. 1H NMR (200 MHz, CDCl3) d: 3.60-3.88 (m, 3H), 4.00-4.12 (m, 1H, Hs) 4.19 (t, J = 9.5 Hz, 1H), 4.35 (dd, J6,5 = 4.7 HZ, J6,6, = 10. 2 Hz, 1H, <BR> <BR> <BR> H6), 4.94 (dd, 2H, CH2Ph), 5.63 (s, 1H, H7), 6. 38 (d, JI, 2 = 3.7 Hz, 1H, H1), 7.31-7.51 (m, 10H, ArH), 8.75 (s, 1H, NH).

6-O-[2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-α-D- glucopyranosyl]-2,3: 4,5-di-O-cyclohexyliden-1-O- menthoxycarbonyl-lD-myo-inositol (18a). A mixture of 56 mg (0.11 mmol) of 17ß, 23 mg (0.04 mmol) of 6 and powdered 4A molecular sieves in 1.1 mL of ethyl ether was stirred for 45 min at room temperature. At this time, 76 mL (0.008 mmol) of a solution of trimethylsilyl triflate in ethyl ether (0.108M) were added dropwise. The reaction mixture was stirred for 15 min, quenched with

triethyl amine, diluted with CH2Cl2, filtered through celite and evaporated in vacuo. Silica-gel column chromatography (hexane-EtOAc, 12: 1) afforded 18 (37 mg, <BR> <BR> <BR> 95%) as a 10: 1 a/ mixture of anomers. Data for 18a: Rf (hexane-EtOAc, 6: 1) = 0.38. 1H NMR (500 MHz, CDCl3) d: 0.77 (d, 3H, CH3Mnt), 0.88 (d, 3H, CH3Mnt), 0.92 (d, 3H, CH3Mnt), (m, 2H, Mnt), 1.27-1. 74 (m, 25H, cyclohex, Mnt), 1.90-2.02 (m, 1H, Mnt), 2.10-2.18 (m, 1H, Mnt), 3.41 (dd, J2b, 3b = 9. 8 Hz, J2b. lb = 3.9 Hz, 1H, H2b) @ 3.57 (dd, J5a,6a = 10.7 Hz, Jsa, 6a= 8.8 Hz, 1H, H5a), 3.72 (Yt, 9.3Hz,J4b,5b=9.8Hz,1H,H4b),3.74(t,J6b,6b@= JSb, 5b = 10.0 Hz, 1H, H6b), 3.99 (dd, J4,,, 5a = 10. 7 Hz, Jq,, 3a Hz,1H,H4a),4.05(dd,J6a,5a=8.8Hz,J6a,1a=2.9Hz,=7.8 1H, H6a, 4.07 (Yt, J3b, 4b = 9.3 Hz, J3b 2b = 9.8 Hz, 1H, H3b), 4.14 (dt, J5b, 6b'= 4.9 Hz, J5b, 6b = 10.2 Hz, J5b, 4b = 9.8 Hz, 1H, (dd,J6b@,6b=10.0Hz,J6b@,5b=5.1Hz,1H,4.31 H6b@), 4. 39 (t, 7.3 Hz, 1H, H3a), 4.50-4.55 (m, 1H, Mnt), 4.56 (dd, J2a, 3a = 6.9 Hz, J2a,1a = 4.1 Hz, 1H, H2a), 4 86 (dd, 2H, CH2Ph), 4.95 (Yt, Jazz 2a = 3.9 Hz, Jla, sa- 2.9 Hz, 1H, Hla), 5.27 (d, Jlb, 2b = 3.9 Hz, 1H, Hlb), 5. 57 (s, 1H, H7b), 7.25-7. 35 (m, 10H, ArH). 13C NMR (CDC13,50 MHz) d: 16.1,20.7,21.9,23.2,23.5,23.7,23.8,24.9, 34.0,34.6,36.2,36.4,36.6,40.6, 1,74.9,76.2,76.3,76.4, 76.7,79.0,82.6,97.5 (C-lb), 101.4 (C-7b), 112.1 (Cipso cyclohex), 113.3 (Cipso cyclohex), 125.9,126.0,127.8, 128.0,128.2,128.3,128.4,137.3,137.9,154.2.

6-O-[2-Azido-3,6-di-O-benzyl-4-O-(tert- butyldimethylsilyl)-2-deoxy-a-D-glucopyranosyl]-2,3: 4,5- <BR> <BR> <BR> di-O-cyclohexylidene-1-O-menthoxycarbonyl-lD-myo-inositol< ;BR> <BR> <BR> <BR> <BR> (19a). A mixture of 180 mg (0.28 mmol) of 15ß, 73 mg (0.14 mmol) of 6 and powdered 4A molecular sieves in 3 mL of ethyl ether was stirred for 45 min at room

temperature. At this time, 194 mL (0.02 mmol) of a solution of trimethylsilyl triflate in ethyl ether (0.108M) were added dropwise over 45 min. The reaction mixture was stirred for 15 min, quenched with triethyl amine, diluted with CH2Cl2, filtered through celite and evaporated in vacuo. Silica-gel column chromatography (hexane-EtOAc) afforded 19 (102 mg, 73%) as a 9: 1 oe/ß mixture of anomers. Data for 19a. Rf (hexane-EtOAc, 3: 1) = 0. 76. M. p.: 72-74°C. [α]D + 47.2 (c 1.36, CHCl3).

1H NMR (500 MHz, CDCl3) d:-0.03 (s, 3H, CH3Si), 0.02 (s, 3H, CH3Si), 0.76 (d, 3H, Mnt), 0.86 (s, 9H, tBu), 0.87 (d, 3H, CH3Mnt), 0.92 (d, 3H, CH3Mnt), 1.00-1.10 (m, 2H, Mnt), (m, 25H, cyclohex., Mnt), 1.90-1.97 (m, 1H, Mnt), (m, 1H, Mnt), 3.32 (dd, J2b, 3b = 9. 8 Hz, J2b, lb = 3. 4 Hz, 1H, H2b), 3.59 (dd, J5a, 4a = 10.7 Hz, J5a,6a = 8.8 Hz, 1H, H5a), 3.64 (dd, J6b, 10.9 Hz, J6b, sb = 1. 9 Hz, 1H, H6b), 3.72 (dd, J6b', 6b = 10. 9 Hz, J6b', 5b = 3.7 Hz, 1H, H6b'), 3.76 (Yt, J3b,4b = J3b,2b = 9. 8 Hz, 1H, H3b) 3.81 (Yt, J4b,3b = J4b,5b = 9. 8 Hz, 1H, H4b), 3.98 (dd, J9,, sa = 10. 7 Hz, J4., 3a = 7. 3 Hz, 1H, H4a), 3.98-4.02 (m, 1H, H5b), 4.14 (dd, Jazz 5a = 8.8 Hz, J6a,1a = 3.4 Hz, 1H, H6a), 4.37 (t, Jasa, 2a = J3a 4a = 7.3 Hz, 1H, H3a), 4.52 (dt, 1H, Mnt), 4.55 (dd, 4.58(dd,J2a,3a=7.3Hz,J2a,1a=3.4Hz,CH2Ph), 1H, H2a), 4.82 (dd, 2H, CH2Ph), 5. 00 (t, J1a,2a = J1a,6a = 3.4 Hz, 1H, Hla) 5. 31 (d, Jlb, 2b = 3.4 Hz, 1H, Hlb), 7.25-7.35 (m, 10H, ArH). 13C NMR (50 MHz, CDC13) d:-4.95,-3.65, 16.13,18.04,20.76,21.92,23.22,23.52,23.63,23.83, 23.90,24.90,25.06,25.92,31.43,34.09,34.53,36.33, 36.65,40.62,47.01,63.46,68.40,70.66,72.14,73.26, 74.51,76.21,76.55,76.71,77.18,79.21,80.39,96.80, 112.06,113.23,127.30,127.42,128.24,138.26,154.14.

Anal. Calcd. for C55H81N3O12Si: C, 65.77; H, 8.13; N, 4.28.

Found: C, 65.72; H, 8.40; N, 4.28.

6-O-(2-Azido-3,6-di-O-benzyl-2-deoxy-α-D-glucopyranosyl- 2,3: 4,5-di-O-cyclohexylidene-1-O-menthoxycarbonyl-lD-myo- inositol (20α). To a solution of 82 mg (0.08 mmol) of 19a in 0.8 mL of THF were added 204 mL (0.24 mmol) of a 1M solution of tetrabutylammonium fluoride in THF. The reaction mixture was stirred for 45 min, quenched with water, diluted and extracted with CH2Cl2 and washed with brine. Silica-gel column chromatography (hexane-EtOAc, <BR> <BR> <BR> <BR> 6: 1) afforded 20a (61 mg, 84%). Rf (hexane-EtOAc, 3: 1) = 0.46. M. p.: 74-76°C. [α]D + 25.9 (c 0.99, CHCl3). 1H NMR (200 MHz, CDCl3) d: 0.77 (d, 3H, Mnt), 0.89 (d, 3H, CH3Mnt), 0.93 (d, 3H, CH3Mnt), (m, 2H, Mnt), (m, 25H, cyclohex., Mnt), 1.87-2.05 (m, 1H, Mnt), 2.07-2.20 (m, 1H, Mnt), 2. 75 (d, JOH, 4b = 2.2 Hz, 1H, OH), 3. 35 (dd, J2b,3b = 9.9 Hz, J2b,1b = 3-6 Hz, 1H, H2b), 3.57 (dd, J, 4a = 10.8 Hz, Jasa 6a = 8.5 Hz, 1H, H5a), 3.67 (dd, j6b b- = 10.1 Hz, J6b, 5b = 4. 9 Hz, 1H, H6b), 3.77-3.86 (m, 3H), 4.00 (dd, J4a 5a = 10.8 Hz, J4a,3a = 7.4 Hz, 1H, H4a), 4 01-4. 09 (m, 1H), 4.06 (dd, Jazz 5a = 8.5 Hz, J6a,1a = 2. 6 Hz, 1H, H6a), 4.40 (t, Jazz 4a = J3a,2a = 7.2 Hz, 1H, H3a), 4.46-4.60 (m, 2H, H2a, Mnt), 4.58 (dd, 2H, CH2Ph), 4.89 (dd, 2H, CH2Ph), 4.99 (dd, Jla 2a = 3.9 Hz, Jla, 6a = 2-6 Hz, 1H, H1a), 5.26 (d, Jlb, 2b = 3-6 Hz, 1H, H1b), 7.29 - 7.45 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d: 16.12,20.73,21.92, 23.22,23.50,23.65,23.81,23.88,24.94,25.04,25.98, 31.42,34.07,34.55,36.23,36.49,36.57,40.61,46.98, 62.50,69.67,70.50,72.85,73.16,73.74,76.19,76.55, 76.70,79.23,79.72,97.15,112.12,113.24,127.66, 127.83,127.90,128.00,128.44,128.53,137.69,138.21, 154.16. Anal. Calcd. for C49H67N3012: C, 66.12 ; H, 7.59; N, 4.72. Found: C, 65.91 ; H, 7.67 ; N, 4.52.

1,6-Anhydro-3-O-(4-methoxybenzyl)-ß-D-mannopyranose (23).

To a solution of 3.5 g (12.5 mmol) of 1,6-anhydro-2,3-O-

125mLendo-(4-methoxybenzyliden)-ß-D-mannopyranose[36]in de CH2Cl2 at 0°C was added slowly 40 mL (40 mmol) of a solution of DIBALH in toluene (1M). After 5 h, Et3N and MeOH were added. The crude reaction mixture was diluted with EtOAc, washed with a solution of HCl (10%) and extracted with EtOAc. The organic layers were evaporated and the crude was purified by silica-gel column chromatography (CH2Cl2-MeOH, 20: 1) affording 2.8 g (79%) of 23. Rf (CH2Cl2-MeOH 20: 1) = 0.16. M. p. 108-110°C.

[α]D :-66.8 (c 0.72, CHC13).'H RMN (acetone, 200 MHz) d: 2.88 (s, 1H, OH), 3.33 (d, 1H, OH), 3,56 (bt, 1H, H-6), 3.62-3.68 (m, 1H, H2), 3.78 (s, 3H, CH30), 3.92 (d, 1H, H3), 4.08 (d, 1H, H6), 4.27 (d, 1H, H4), 4.40 (d, 1H, H5) 1 4.56 (dd, 2H, CH2Ph), 5.12 (bs, 1H, Hui), 6.91 (d, 2H, ArH), 7.31 (d, 2H, ArH). 13C NMR (CDCl3, 50 MHz) d: 55.1, 64.5,65.8,69.0,73.4,75.7,78.0,101.8 (C-1), 129.2, 129.3,129.5,158.4.

1,6-Anhydro-2,4-di-O-benzyl-3-O-(4-methoxybenzyl)-ß-D- mannopiranose (24). To a solution of 2.4 g (8.5 mmol) of 23 in 20 mL of DMF at room temperature were added 472 mg (18.7 mmol) of NaH and 1.9 mL (25.5 mmol) of BnBr. After 2 h, MeOH was added and the reaction mixture was diluted with EtOAc, washed with H20, dried over Na2SO4 and evaporated. Silica-gel column chromatography (hexano/EtOAc 3: 1) afforded 3.9 g (quantitative yield) of 24. Rf (hexane-EtOAc 2: 1) = 0.31. M. p. 68-70°C. [α]D :- 20.3 (c 0.84, CHCl3). 1H RMN (CDCl3, 200 MHz) d: 3.48 (bt, 1H, H4), 3.60 (dd, J2, 1 = 1.7 Hz, J2, 3 = 5. 3 Hz, 1H, H2), 3.66 (dd, J6, 7.0 Hz, J6,5 = 6.0 Hz, 1H, H6), 3.74 (s, 3H, CH30), 3.74-3. 80 (m, 1H, H3), 4.18 (dd, J6,, 5 = 0. 9 Hz, J6% 6 = 7.1 Hz, 1H, H6.), 4.35-4.56 (m, 7H, H5,3 CH2Ph), 5.41 (bt, 1H, Hui), 6.89 (d, 2H, ArH), 7.26-7.40 (m, 12H, ArH0. 13C NMR (CDCl3, 50 MHz) d: 55.1,64.8,

71.1,71.2,72.7,73.9,74.4,76.4,100.0 (C-1), 127.5, 127.6,127.8,128.2,128.3,129.7,137.6,137.9,159.2.

1,6-di-O-Acetyl-2,4-di-O-benzyl-3-0- (4-methoxybenzyl)-a- D-mannopyranose (25). A solution of 4.88 g (10.55 mmol) of 24 and 240 mL (1.24 mmol) of trimethylsilyltrifluoromethanesulphonate in 33 mL of acetic anhydride was stirred for 1 h at 0°C and 2 h at room temperature. The reaction mixture was diluted with EtOAc, carefully washed with a saturated aqueous solution of NaHCO3, extracted with EtOAc and dried over Na2SO4.

Silica-gel column chromatography afforded 25a (4.72 g, <BR> <BR> <BR> <BR> 79%) and 24 (169 mg, 3%). Data for 24a: Rf (hexane-<BR> <BR> <BR> <BR> <BR> <BR> EtOAc 2: 1) = 0.36. [a] D + 28.1 (c 0.78, CHC13). lH NMR (200 MHz, CDCl3) d: 2.04 (s, 3H, CH3CO), 2.05 (s, 3H, CH3CO), 3.72 (Yt, J2,1 = J2, 3 = 2.4 Hz, 1H, H2), 3.81 (s, 3H, CH'3O), 3.82-4. 03 (m, 3H, H3, H4, H5), 4.30-4. 33 (m 2H, H6a, Hsb) r 4.54 (s, 2H, CH2Ph), 4.75 (dd, 2H, CH2Ph), 4.77 (dd, 2H, CH2Ph), 6.18 (d, J1,2 = 2.1 Hz, 1H, H1), 6.83 -7.40 (m, 14H, ArH). 13C NMR (50 MHz, CDC13) d: 20.79, 20.91,55.24,63.17,71.71,72.39,73.38,73.80,75.25, 78.77,91.65,113.80,113.95,127.78,127.86,128.11, 128.35,128.42,129.37,130.04,137.78,138.00. Anal.

Calcd. for C32H36O9: C, 68.08; H, 6.43. Found: C, <BR> <BR> <BR> <BR> 6.12. Data for 24ß: Rf (hexane-EtOAc, 2: 1) = 0.31. [ajo + 0.7 (c 4.22, CHCl3). 1H NMR (200 MHz, CDCl3) d: 2.05 (s, 3H, CH3CO), 2.09 (s, 3H, CH3CO), 3.55-3.66 (m, 1H, Hs) 3.63 (dd, J3, = 2.8 Hz, J3, 4 = 9.1 Hz, 1H, H3), 3.82 (s, 3H, CH30), 3.87-3.96 (m, 2H, H2, H4), (m 2H, H6a, H6b), 4.57 (dd, 2H, CH2Ph), 4.76 (dd, 2H, CH2Ph), 4.87 (s, 2H, CH2Ph), 5.60 (d, Jl, 2 = 0.9 Hz, 1H, H1), 6.84- 7.48 (m, 14H, ArH)."C NMR (50 MHz, CDCl3) d: 14.10, 20.80,20.93,55.16,60.27,63.25,71.78,73.37,73.81, 74.07,74.36,75.03,81.75,92.92,113.81,127.61,

127.79,128.00,128.10,128.14,128.35, 129, 24,129.76, 137.83,138.16,159.28,168.8,170.74. Anal. Calcd. for C32H36O9 : C, 68.08; H, 6.43. Found: C, 67.84; H, 6.71.

1,6-di-O-Acetyl-2,4-di-O-benzyl-a-D-mannopyranose (26).

To a solution of 100 mg (0.18 mmol) of 25 in 1.5 mL of CH2Cl2 was added 50 mL of trifluoroacetic acid in 2 mL of CH2Cl2. The reaction mixture was stirred for 3 h at room temperature, neutralized with a saturated aqueous solution of NaHCO3, extracted with CH2Cl2 and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 26 (77 mg, 98%). Rf (hexane-EtOAc, 2: 1) = <BR> <BR> <BR> <BR> 0.24. [a], + 29.7 (c 1.52, CHCl3). 1H NMR (200 MHz, CDCl3) d: 2.08 (s, 3H, CH3CO), 2.09 (s, 3H, CH3CO), 2.43 (d, JOH, 3 = 9.7 Hz, 1H, OH), 3.68 (t, J4,3 = J4,5 = 9. 6 Hz, 1H, H4), 3. 74 (dd, J3 3 = 3.9 Hz, J2, 1 = 1.8 Hz, 1H, H2), 3.88 (dd., J54 = 9.8 Hz, Jus, sua = 4. 6 Hz, JI, 6b = 2.3 Hz, 1H, Ho), 4.01 (dt, J3,4 = J3,OH = 9.6 Hz, J3, 2 = 3.8 Hz, 1H, H3), 4.30 (dd, Jazz 6b = 12. 0 Hz, J6a,5 = 4. 6 Hz, 1H, H6a), 4.38 (dd, Jazz 6a = 12.0 Hz, J6b, 5 = 2.3 Hz, 1H, H6b), 4.71 (dd, 2H, CH2Ph), 4.78 (dd, 2H, CH2Ph), 6.27 (d, Jl, 2 = 1. 8 Hz, 1H, H1), 7.30-7.41 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d: 20. 80, 20.91,63.14,71.47,71.62,72.67,75.05,75.63,76.78, 90.73,127.98,128.11,128.25,128.48,128.64,128.64, 137.15,137.91,168.91,170.74. Anal. Calcd. for C24H2808: C, 64.86; H, 6.35. Found: C, 64.44; H, 6.38.

1,6-di-O-Acetyl-2, 4-di-O-benzyl-3-O-(tert- butyldiphenylsilyl)-a-D-mannopyranose (27). To a solution of 1.40 g (3.15 mmol) of 26,170 mg (1.39 mmol) of 4- dimethylaminopyridine and 857 mg (12.60 mmol) of imidazole in 5 mL of DMF, were added 1.64 mL (6.30 mmol) of tert-butyldiphenylsilyl chloride. The reaction mixture was stirred for 17 h at room temperature, diluted

with ethyl ether, washed with water and brine and dried over Na2SO4. Silica-gel column chromatography (hexane- EtOAc, 10: 1,4: 1) afforded 27 (1.91 g, 89%). Rf (hexane- EtOAc, 2: 1) = 0.55. M. p. = 107-109°C [α]D + 44.8 (c 1.13, CHCl3). 1H NMR (200 MHz, CDCl3) d: 1.14 (s, 9H, tBu), 1.89 (s, 3H, CH3CO), 2.04 (s, 3H, CH3CO), 3.03 (bs, 1H, H2), 3.85 (ddd, J54 = 9.6 Hz, J5,6a = 4.3 Hz, J5,6D = 2.2 Hz, 1H, H5), 4.07 (bt, J4,3 = J4, 5 = 9.2 Hz, 1H, H4), 4.22-4.37 (m, 2H, H6a, H6b) 4.32 (dd, J3, 4 = 8.9 Hz, J3, 2 = 3.1 Hz, 1H, H3), 4.42 (dd, 2H, CH2Ph), 4. 58-4.72 (bm, 1H, CH2Ph), 4.99-5.12 (bm, 1H, CH2Ph), 5. 95 (d, Jl, 2 =2. 1 Hz, 1H, H1), 7.24-7.77 (m, 20H, ArH). 13C NMR (50 MHz, CDCl3) d: 19.32,20.81,27.06,63.22,72.05,72.69,72.99, 75.23,76.36,77.05,91.30,127.21,127.31,127.46, 127.66,127.72,127.77,128.00,128.18,128.38,129.83, 130.03,133.12,134.13,135.92,136.08,137.86,138.16.

Anal. palcd. for C40H46O8Si : C, 70.36; H, 6.79. Found: C, 70.61; H, 6.77.

Phenyl 6-O-acetyl-2, 4-di-O-benzyl-3-O-(tert- butyldiphenylsilyl)-1-thio-a-D-mannopyranoside (28a). To a solution of 1.80 g (2.64 mmol) of 27 in 26 mL of CH2Cl2 at room temperature were added 592 mL (4.80 mmol) of thiophenol and 1.32 mL (10.5 mmol) of borontrifluoride diethyl etherate. The reaction mixture was stirred for 30 min, quenched with a saturated aqueous solution of NaHCO3 and the organic layer dried over Na2SO4. Silica- gel column chromatography (hexane-EtOAc, 10: 1) afforded 28α (1.735 g) and 28 (115 mg) in a total yield of 97% (15: 1 a/ (3 ratio). Data for 28a. Rf (hexane-EtOAc, 5: 1) = 0. 40. [a] D + 126.1 (c 1.21, CDCl3). 1h NMR (200 MHz, CDCl3) d: 1.17 (s, 9H, tBu), 2.02 (s, 3H, CH3CO), 3.29 (m, 1H, H2), 3.97-4.07 (m, 1H, H4), 4.21-4.37 (m, 5H, H5, H6at H6b , CH2Ph), 4. 37 (dd, J3, 4 = 8.8 Hz, J3, 2 = 2.8 Hz, 1H,

H3), 4.59-4.68 (bm, 1H, CH2Ph), 4.97-5.18 (bm, 1H, CH2Ph), 5. 26 (d, J1, 2 = 1.5 Hz, 1H, H1), 7.21-7.84 (m, 25H, ArH). 13C NMR (50 MHz, CDCl3) d: 19.32,20.79,27.17, 29.67,63.57,71.03,71.83,74.04,74.08,75.25,76.13, 77.19,79.59,85.23,127.28,127.36,127.42,127.27, 127.76,127.89,127.97,128.17,128.26,128.36,128.81, 129.82,129.96,131.62,133.11,134.31,136.08,138.00, 138.26,170.72. Anal. Calcd. for CHOgSSi: C, 72.10; H, 6.60 ; S, 4.37. Found: C, 72.31; H, 6. 35; S, 4.12.

Phenyl 2,4-di-O-benzyl-3-O-(tert-butyldiphenylsilyl)-1- thio-a-D-mannopyranoside (29). To a solution of 100 mg <BR> <BR> <BR> <BR> <BR> (0.14 mmol) of 28a in 2 mL of methanol was added 0.4 mL of sodium methoxide in methanol (1M). The reaction mixture was stirred for 1 h at room temperature, neutralized with Amberlite IR-120 H+, filtered and evaporated. Silica-gel column chromatography (hexane- EtOAc, 3: 1) afforded 29 (95 mg, quantitative yield). Rf (hexane-EtOAc, 3: 1) = 0.46. M. p. = 46-48°C. [α]D + 131.1 (c 1.17, CHCl3). 1H NMR (200 MHz, CDC13) d: 1.16 (s, 9H, tBu), 3.32 (m, 1H, H2), 3.77-3.81 (m, 2H), 4.05-4.08 (m, 2H, H4), 4.32 (dd, 2H, CH2Ph), 4.38 (dd, J3, = 8.8 Hz, J32 = 3.1 Hz, 1H, H3), 4.62-4.77 (bm, 1H, CH2Ph), 4.97- 5.10 (bm, 1H, CH2Ph), 5.20 (d, Jl 2 = 1.7 Hz, 1H, H1), 7.21 -7.84 (m, 25H, ArH). 13C NMR (50 MHz, CDC13) d: 19.31, 27.16,62.21,72.24,73.34,73.89,75.16,76.02, 127.39,127.41,127.63,127.71,127.88,128.23,128.33, 128.90,129.77,129.92,131.66,133.21,134.46,136.07, 138.27. Anal. Calcd. for C42H46OsSSi: C, 73.10; H, 6.71; S, 4.64. Found: C, 73.12; H, 6.43; S, 4.37. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>3-O-Benzyl-4,6-0-benzylidene-2-deoxy-2-phthalimido- p-D-<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> glucopyranosyl fluoride (30). To a solution of 100 mg (0.17 mmol) of phenyl 3-O-benzyl-4, 6-O-benzylidene-2-

deoxy-2-phthalimido-1-thio-b-D-glucopyranoside[46] in 1.7 mL of CH2Cl2 at-15 C, 68 mL (0.52 mmol) of diethylaminosulphur trifluoride were added dropwise followed by 46 mg (0.26 mmol) of NBS. The reaction mixture was stirred for 4 h 30 min, quenched with a saturated solution of NaHCO3 in water/ice, extracted with CH2Cl2 and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 4: 1) afforded 30 in quantitative yield. Rf (toluene-EtOAc, 10: 1) = 0.56.

M. p.: 173-175°C. [α]D + 62.0 (c 0.99, CHCl3). 1H NMR (200 MHz, CDCl3) d: (m, 1H), (m, 2H), 4.24-4.52 (m, 3H), 4.65 (dd, 2H, CH2Ph), 5.64 (s, 1H, H70, 5.90 (dd, 1H, JF, 1 = 53.4 Hz, J1, 2 = 7.6 Hz, H1), 6. 84- 7.80 (m, 14H, ArH). 13C NMR (50 MHz, CDCl3) d: 41.98, 55.57,55.98,65.72,65.82,68.36,73.74,73.93,74.15, 82.36,101.48,102.93,107.22,123.49,126.04,127.52, 128. 07. J, 128.30,129.12,131.51,134.04,137.04,137.62.

Anal. Calcd. for C28H24FNO6 : C, 68.70; H, 4.94; N, 2.86.

Found: C, 5.10; N, 2.85.

Phenyl 0- (3-0-benzyl-4, 6-0-benzylidene-2-deoxy-2- <BR> phthalimido-ß-D-glucopyranosyl)-(1-6)-2, 4-di-O-benzyl-3-<BR> O-(tert-butyldiphenylsilyl)-1-thio-a-D-mannopyranoside (31). A mixture of 475 mg (0.688 mmol) of 29,800 mg (2.68 mmol) of zirconocene dichloride, 1.39 g (5.37 mmol) of silver triflate and powdered 4A molecular sieves in 14 mL of CH2Cl2 was stirred in the dark and at room temperature for 30 min. At this time, the reaction mixture was cooled to-40°C and 437 mg (1.3 mmol) of 30 in 6 mL of CH2C12 were added dropwise over 30 min. After stirring for lh 30 min, the mixture was quenched with a saturated aqueous solution of NaHCO3, diluted with CH2Cl2, washed with brine, dried over Na2SO4, concentrated and chromatographed (diethyl ether/cyclohexane, 1: 2) to yield

31 (654 mg, 82%). Rf (hexane-EtOAc, 3: 1) = 0.36. M. p.

82-85°C. [a] D + 89.6 (c 0.95, CHCl3). 1H NMR (500 MHz, CDCl3) d: 0.99 (s, 9H, tBu), 3.15 (bs, 1H, H2d), 3.61 (dt, Jsd 4d = J5d, 6d = 9.9 Hz, J5d, 6d = 4. 9 Hz, 1H, H5d), 3. 70- 3.79 (m, 4H), 3.99-4.08 (m, 3H), 4.17-4.25 (m, 3H), (m, 2H), 4.41-4.54 (m, 2H), 4.63 (dd, 2H, CH2Ph), 5.13 (bs, 1H, Hc), 5.29 (d, Jld, 2d = 8. 3 Hz, 1H, Hld), 5.56 (s, 1H, H7d), 7.18-7.66 (m, 39H, ArH). 13C NMR (50 MHz, CDCl3) d: 19.21,27.09,55.57,66.12,68.48, 68.70,71.57,72.17,73.72,74.03,74.63,75.91,76.66, 76.81,77.20,77.42,78.00,78.15,79.58,82.97,85.27, 99.00,101.30,123.21,126.07,126.94,127.18,127.31, 127.51,127.60,127.99,128.19,128.27,128.80,128.97, 129.63,129.84,131.13,131.65,133.17,133.59,134.35, 134.89,136.03,137.42,138.00,138.31. Anal. Calcd. for C70H69NO1lSSi: C, 72.45; H, 5.99; N, 1.21; S, 2.76. Found: C, 72.21; H, 6.10; N, 1.29; S, 2.57. <BR> <BR> <BR> <BR> <BR> <P>0-(3-O-Benzyl-4, 6-O-benzylidene-2-deoxy-2-phthalimido-ß-<BR> <BR> <BR> <BR> D-glucopyranosyl)-(1#6)-2,4-di-O-benzyl-3-O-(tert- butyldiphenylsilyl)-a-D-mannopyranose (32). To a solution of 105 mg (0.09 mmol) of 31 in 1.8 mL of acetone in the dark at-15°C, 24 mg (0.14 mmol) of NBS were added. Ten minutes later, the reaction mixture was quenched with a saturated aqueous solution of NaHCO3, diluted and extracted with EtOAc, washed with brine and dried. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 31 (91 mg, 94%). Rf (hexane-EtOAc, 3: 1) 0.15. M. p. 74-76°C, 1H NMR (200 MHz, CDCl3) d: 1.04 (s, 9H, tBu), 2.60 (d, JoH, in= 2.5 Hz, 1H, OH), 3.03 (Yt, J2c 1c = J2c, 3c = 2-8 Hz, 1H, H2c), 3.41-3. 90 (m, 7H), 4.11- <BR> <BR> <BR> 4.80 (m, 12H), 5.55 (d, Jld 2d = 8.3 Hz, 1H, Hld), 5.60 (s, 1H, H7d), (m, 34H, ArH). 13C NMR (50 MHz, CDCl3) d: 19.22,27.18,55.88,66.13,68.19,68.85,72.51,

72.79,73.21,74.01,74.36,74.57,74.65,75.79,76.67, 77.20,77.40,78.19,78.32,83.26,92.32,98.86,101.38, 123.24,126.09,127.34,127.48,127.62,127.68,127.80, 129. 56, 129. 69, 129.83,131.56,131.63,133.53,133.76,133.91,134.37, 136.12,137.44,137.80,137.98,138.59. Anal. Calcd. for C64H65NO12Si: C, 71.96; H, 6.13 ; N, 1.31. Found: C, 71.71; H, 5.85; N, 1.37. <BR> <BR> <BR> <BR> <BR> <BR> <P>0-(3-O-Benzyl-4, 6-O-benzylidene-2-deoxy-2-phthalimido-ß-<BR> <BR> <BR> <BR> <BR> <BR> D-glucopyranosyl)- (l-6)-2, 4-di-O-benzyl-3-0- (tert-<BR> <BR> <BR> <BR> <BR> <BR> butyldiphenylsilyl)-a-D-mannopyranosyl trichloracetimidate (33). To a solution of 53 mg (0.05 mmol) of 32 in 0.25 mL of CH2Cl2 at room temperature, were added 50 mL (0.50 mmol) of trichloracetonitrile and 7 mg (0.05 mmol) of flame-dried potassium carbonate. After 4 h, thdtreaction mixture was diluted with CH2Cl2, filtered through celite and evaporated. Silica-gel column chromaography (hexane-EtOAc, 3: 1) afforded 33 (53 mg, <BR> <BR> <BR> <BR> 88%) as a 13: 1 a/ (3 mixture. Data for 33a: Rf (hexane-<BR> <BR> <BR> <BR> <BR> <BR> EtOAc, 3: 1) = 0.36. M. p. 76-78°C. [a] p + 34.2 (c 0.61, CHCl3). 1H NMR (200 MHz, CDC13) d: 1.02 (s, 9H, tBu), 3.21 (m, 1H, H2, 3.56-3.87 (m, 6H), 4.04-4.62 (m, 9H), 4.64 (dd, 2H, CH2Ph), 5.28 (d, Jld2d = 8-2 Hz, 1H, H1d), 5.60 (s, 1H, H7d), 5.74 (m, 1H, Hlc) 7.10-7.65 (m, 34H, ArH), 8.09 (s, 1H, NH). 13C NMR (50 MHz, CDCl3) d: 19.23, 27.13,55.69,66.09,68.84,72.19,72.96,73.87,74.02, 74.76,75.54,76.23,83.04,95.81,99.22,101.32,123.19, 126.08,127.23,127.29,127.52,127.67,127.97,128.19, 128.25,128.96,129.59,129.80,131.72,133.08,133.51, 134.27,136.02,137.44,137.85,138.04,138.33,159.80, 167.54. Anal. Calcd. for C66H6sCl3N2012Si: C, 65.37; H, 5.40 ; N, 2.31. Found: C, 65.10; H, 5.10; N, 2.07.

Phenyl 6-O-Acetyl-2-O-benzyl-3,4-O-isopropylidene-1-thio- ß-D-galactopyranosida (36). To a solution of 193 mg (0.48 mmol) of phenyl 2-O-benzyl-3,4-O-isopropylidene-1- <BR> <BR> <BR> <BR> thio-ß-D-galactopyranoside (35) [45] in 0.77 mL of pyridine and DMAP (cat.) at 0°C, was added dropwise 0.11 mL (1.20 mmol) of acetic anhydride. After stirring for 5 min at 0°C and 90 min at room temperature, the reaction mixture was evaporated. Silica-gel column chromatography (hexane-EtOAc, 4: 1) of the crude afforded 36 (213 mg, quantitative yield). Rf (hexane-EtOAc, 3: 1) = 0.35. [α]D + 9.2 (c 1.10, CHCl3). 1H NMR (300 MHz, CDCl3) d: 1.35 (s, 3H, iPr), 1. 41 (s, 3H, iPr), 2.06 (s, 3H, Ac), 3.54 (dd, J2 3 = 6. 2 Hz, J21 = 9.4 Hz, 1H, H2), 3.94 (dt, J5,4 = 2.1 Hz, J5,6 = 6.0 Hz, 1H, H5), 4.19 (dd, J4 5 = 2.0 Hz, J4, 3 = 5.8 Hz, 1H, H4), 4.28 (t, J3,4 = J3,2 = 6.0 Hz, 1H, H3), 4.34 (d, 6.1Hz,2H,H6a,H6b),4.63(d,J1,2=9.4= Hz, 1H, H1), 4.76 (dd, 2H, CH2Ph), 7.25-7.57 (m, 10H, ArH). 13C NMR (50 MHz, C6D6) d: 20.33,26.29,27.73,63.92, 73.52,73.89,74.42,78.81,79.89,86.38,110.27,127.52, 127.83,128.28,128.92,129.62,130.02,130.24,132.58, 134.82,138.73,169.87. Anal. Calcd. for C24H2806S: C, 64.85 ; H, 6.35; S, 7.21. Found: C, 65.17; H, 6.08; S, 7.25.

6-O-Acetyl-2-O-benzyl-3,4-O-isopropylidene-D- galactopyranose (37). To a solution of 115 mg (0.259 mmol) of 36 in 5 mL of acetone at-15°C was added 60 mg (0.336 mmol) of NBS and 5 mL (0.284 mmol) of water.

After stirring for 10 min, the reaction mixture was quenched with a saturated aqueous solution of NaHCO3, diluted and extracted with EtOAc, washed with brine and dried over Na2SO4. Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 37 (86 mg, 94%). Rf (hexane-EtOAc, 2: 1) = 0.17. M. p. 122-124°C. 1H NMR (200

MHz, CDCl3) d: 1.34 (s, 3H, iPra+b), 1.43 (s, 3H, iPra), 1.46 (s, 3H, iPrb), 2.09 (s, 3H, Aca), 2.10 (s, 3H, Acb), 3.32 (d, JoH, I= 6.4 Hz, 1H, OH), 3.52 (t, J2,3 = J2, 3 = 5-5 Hz, 1H, H2b), 3.67 (dd, J2, 1 = 3.8 Hz, J2, 3 = 5.7 Hz, 1H, H2a) 4. 08 (ddd, J = 2.1 Hz, J = 4.8 Hz, J = 7.0 Hz, 1H, Hsb), (dt, J = 4.3 Hz, J = 1.6 Hz, 1H, H5a), 4.21-4.39 (m, 4H, H6a,H6b),4.45(t,J=6.0Hz,1H,H3a),H4, 4.75 (dd, 2H, CH2Ph), 4.85 (dd, J1,OH = 5.4 Hz, J1,2 = 7. 9 Hz, 1H, Hlb), 5.22 (dd, J12 = 3.8 Hz, J3,OH = 6.3 Hz, 1H, H1a), 7.29-7.39 (m, 5H, ArH). 13C NMR (50 MHz, C6D6) d: 89, 07,75.36,78.46, 66,109.95,110.33,127.92,128.03,128.18, 58,137.41,137.70,170.84. Anal. Calcd. for C18H24O7 : C, 61.36; H, 6.86. Found: C, 61.14; H, 6.66.

6-O-Adetyl-2-O-benzyl-3, 4-O-isopropylidene-D- galactopyranosyl trichloracetimidate (38). To a solution of 81 mg (0.230 mmol) of 37 in 1.2 mL of CH2Cl2 at room temperature, were added 230.5 mL (2.30 mmol) of trichloracetonitrile and 76 mg (0.552 mmol) of flame- dried potassium carbonate. After 5 h 45 min the reaction mixture was diluted with CH2Cl2, filtered through celite and evaporated. Silica-gel column chromatography <BR> <BR> <BR> (hexane-EtOAc, 6: 1) afforded 38a (29 mg) and 38b (76 mg)<BR> <BR> <BR> <BR> <BR> (92% total yield). Data for 38ß: Rf (hexane-AcOEt, 3: 1) = 0. 17. IH NMR (300 MHz, CDC13) d: 1.35 (s, 3H, iPr), 1.42 (s, 3H, iPr), 2.08 (s, 3H, Ac), 3.70 (dd, J2. 3 = 6.3 Hz, J2,1 = 7.3 Hz, 1H, H-2), 4.12-4.17 (m, 1H, H-5), 4.23 (dd, J4,5 = 2.2 Hz, J4,3 = 5.9 Hz, 1H, H-4), 4.30-4o38 (m, 3H, H- 3, H-6a, H-6b), 4.34 (dd, 2H, CH2Ph), 5.76 (d, J1,2 = 7.6 Hz, 1H, H-1), 7.28-7.40 (m, 5H, ArH), 8.66 (s, 1H, NH). <BR> <BR> <BR> <P>Data for 38a: Rf (hexane-AcOEt, 3: 1) = 0. 37. 1H NMR (300 MHz, CDCl3) d: 1.35 (s, 3H, iPr), 1.41 (s, 3H, iPr), 2.05

(s, 3H, Ac), 3.81 (dd., J2, 3 = 6.8 Hz, J21 = 3.5 Hz, 1H, -4.49(m,5H,H3,H4,H5,H6a,H6b),4.76(dd.,H2),4.23 2H, CH2Ph), 6.43 (d, J1. = 3.6 Hz, 1H, H1), 7.28-7.37 (m, 5H, ArH), 8.64 (s, 1H, NH).

Phenyl 0- (6-0-acetyl-2-0-benzyl-3, 4-0-isopropylidene-a-D- <BR> <BR> <BR> <BR> galactopyranosyl)-(1#6)-2-O-benzyl-3,4-O-isopropylidene- 1-thio-ß-D-galactopyranoside (39). A mixture of 64 mg (0.129 mmol) of 38ß, 45 mg (0.112 mmol) of 35 and activated powdered 4A molecular sieves in 2.1 mL of ethyl ether was stirred for 90 min at room temperature. At this time, 155 mL (0.017 mmol) of a solution of trimethylsilyl triflate in ethyl ether (0.108M) were added. The reaction mixture was stirred for 45 min, quenched with triethyl amine, diluted with CH2Cl2, filtered through celite and evaporated in vacuo. Silica- gel column chromatography (hexane-EtOAc) afforded 39a (62 <BR> <BR> <BR> <BR> mg) and 39p (10 mg) in a total yield of 86%. Data for<BR> <BR> <BR> <BR> <BR> <BR> <BR> 39α . Rf (hexane-EtOAc, 2: 1) = 0.42. M. p. : 45-47°C. [a] D F 48.3 (c 0.88, CHCl3). 1H NMR (300 MHz, C6D6,30 °C) d: 1.24 (s, 3H, iPr), 1.26 (s, 3H, iPr), 1.35 (s, 3H, iPr), 1.41 (s, 3H, iPr), 1.77 (s, 3H, Ac), 3.50-3.59 (m, 2H, H5e, (dd,J2e,3e=6.3Hz,J2e,1e=9.5Hz,1H,H2e),3.69 3.71 (dd, Jzf, 3f = 7.7 Hz, J2f,1f = 3.5 Hz, 1H, H2f), 3.76 (dd, J4e se = 1.9 Hz, J4e 3e = 5. 7 Hz, 1H, H4e), 3.85 (dd, 2.6hz,J4f,3f=5.5Hz,1H,H4f),4.05(t,J3e,4e=J4f,5f= <BR> <BR> <BR> <BR> 6.0Hz,1H,H3e),4.19(dd,J6e@,6e=9.5Hz,J6e@,5e=J3e,2e= 7.0 Hz, 1H, H6e), 4.44 (ddd, J5f, 4f = 2.6 Hz, Je, 6f = 8. 0 Hz, J5 6f = 4.1 Hz, 1H, H5f), (m, 2H, H6f, H6f), 4.56 (dd, Jazz 4f = 5.5 Hz, J3f,2f = 7.7 Hz, 1H, H3f), 4.68 (d, jale, 2e = 9. 5 Hz, 1H, H1e), 4.75 (dd, 2H, CH2Ph), 4.84 (dd, 2H, CH2Ph), 4.96 (d, Jlf 2f = 3.5 Hz, 1H, Hlf), 7.01-7.64 (m, 15H, ArH). 13C NMR (50 MHz, CDC13) d: 20.82,26.29, 27.72,27.96,63.35,65.56,66.90,72.43,73.37,73.73,

74.90,75.85,76.18,78.00,79.59,84.74,96.68,109.15, 110.14,126.58,127.76,127.89,128.19,128.25,128.32, 128.76,129.76,134.57,137.65,138.06,170.59. Anal.

Calcd. for CHOnS: C, 65.20; H, 6.57; S, 4.35. Found: C, 65.05 ; H, 6.54; N, 4.14. Data for 39ß. Rf (hexane-AcOEt, 2: 1) = 0.33. 1H NMR (300 MHz, C6D6,30 °C) d: 1.33 (s, 3H, iPr), 1.35 (s, 3H, iPr), 1.37 (s, 3H, iPr), 1. 42 (s, 3H, iPr), 2.09 (s, 3H, Ac), 3.39 (dd, J2f,3f = 6. 4 Hz, J2f, lf = 7.8 Hz, 1H, H2f), 3.55 (dd, J2e, 3e = 6.1 Hz, J2e,1e = 9.2 Hz, 1H, H2e), 3.88 (dt, 5f, 6f = J5f, 6f = 6.1 Hz, J5f, 4f = 2.0 Hz, 1H, H5f), (m, 4H), 4.10 (dd, J4f,5f = 2.0 Hz, J4f, 3f = 5.7 Hz, 1H, H4f), 4. 14 (t, J3f, 4f J3f, 2f 6 . 0 Hz, 1H, (t,J3e,4e=J3e,2e=5.9Hz,1H,H3e),4.33(d,4.28 J6e,5e=6.1Hz,2H,H6e,H6e@),4.42(d,J1f,2f=7.8J6e@,5e Hz, 1H, H1f), 4.72 (d, Jle 2e = 9. 2 Hz, 1H, H1e), 4.66-4. 84 (m, 4H, 2 CH2Ph), 7.16-7.53 (m, 15H, ArH). 13C NMR (50 MHz, CDCl3) d: 20.85,26.30,27.66,63.47,69.09,70.70, 73.39,73.44,73.87,75.81,77.96,78.72,79.16,79.42, 110.12,110.21,127.01,127.46,127.73, 28,128.84,131.12,137.83,138.22,170.70. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>0-(6-O-Acetyl-2-O-benzyl-3, 4-O-isopropylidene-a-D-<BR> <BR> <BR> <BR> <BR> <BR> galactopyranosyl)-(1#6)-2-O-benzyl-3,4-O-isopropylidene- D-galactopyranose (40). To a solution of 233 mg (0. 316 <BR> <BR> <BR> <BR> mmol) of 39a in 6.5 mL of acetone at-15°C, were added 73 mg (0.411 mmol) of NBS and 6.3 mL (0.348 mmol) of water.

After stirring for 5 min, the reaction was quenched with a saturated aqueous solution of sodium bicarbonate. The mixture was diluted and extracted with EtOAc and washed with brine. Silica-gel column chromatography (hexane- EtOAc, 3: 1) afforded 40 (203 mg, quantitative yield). Rf (hexane-EtOAc, 2: 1) = 0. 12. lH NMR (200 MHz, CDCl3) d: 1.30 (s, 3H, iPr), 1.33 (s, 3H, iPr), 1.38 (s, 3H, iPr), 1.40 (s, 3H, iPr), 2.05 (s, 3H, Aca), 2.06 (s, 3H, Acb),

2.74 (s, 1H, OH), 3.37 (t, J2e,3e = J2e,1e = 6.3 Hz, 1H, H2eb), 3-52 (dd, J2f 3f = 7.7 Hz, J2f if = 3.6 Hz, 1H, H2f), J2e,3e=5.7Hz,J2e,1e=3.7Hz,1H,H2ea),3.68-3.63(dd, 3.92 (m, 2H), 4.00-4.46 (m, 8H), 4.66-4.84 (m, 6H), 4.82 (m, 1H, H1ea0, 7. 26-7. 38 (m, 10H, ArH). 13C NMR (50 MHz, CDCl3) d: 20.85,21.03,25.78,25.89,26.34,27.31, 27.41,28.02,63.71,63.87,65.38,65.56,67.34,67.60, 67.88,71.40,72.26,72.35,72.97,73.07,73.50,73.68, 74.20,75.41,75.88,75.97,78.31,78.58,79.22,79.31, 79.54,90.54,96.20,97.08,97.28,109.37,109.41, 109.57,109.93,127.72,127.81,127.86,127.97,128.01, 128.14,128.33,128.50,137.59,137.99,138.16,138.23, 170.01.171.75. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>0-(6-O-Acetyl-2-O-benzyl-3, 4-O-isopropylidene-a-D-<BR> <BR> <BR> <BR> <BR> <BR> galactopyranosyl)-(1#6)-2-O-benzyl-3,4-O-isopropylidene- D-galactopyranosyl trichloracetimidate (41). To a solution of 185 mg (0.287 mmol) of 40 in 1.5 mL of CH2Cl2, were added 288 mL (2.870 mmol) of trichloroacetonitrile and 80 mg (0.574 mmol) of flame-dried potassium carbonate. The reaction mixture was stirred for 2 hours, diluted with CH2Cl2 and filtered through celite. The solvent was evaporated at reduced pressure and the crude was purified by silica-gel column chromatography (hexane- <BR> <BR> <BR> <BR> EtOAc, 4: 1), affording 41a (69 mg) and 41ß (111 mg) (80%<BR> <BR> <BR> <BR> <BR> <BR> <BR> total yield). Data for 41a. Rf (hexane-EtOAc, 2: 1) = 0. 49. 1H NMR (200 MHz, CDCl3) d: 1.31 (s, 3H, iPr), 1.32 (s, 3H, iPr), 1.37 (s, 3H, iPr), 1.39 (s, 3H, iPr), 2.04 (s, 3H, Ac), 3.51 (dd, J2f, 3f = 7.7 Hz, J2f,1f = 3.4 Hz, 1H, H2f), , 3.72 (dd, J6e,6e = 10.5 Hz, J6e,5e = 5. 2 Hz, 1H, H), 3.80 (dd, J2e, 3e = 6. 6 Hz, J2e, le = 3. 6 Hz, 1H, H2e), 3.88 (dd, 176e', 6e = 10.5 Hz, J6e@, se = 7.1 Hz, 1H, H6e@), 4.14 (dd, J = 2.5 Hz, J = 5.6 Hz, 1H), 4.17-4.50 (m, 5H, H3et H3f, H5e, H5f), 4. 30 (d, Jazz 6f = 8.4 Hz, 2H, H6f, H6f), 4.65-

4.85 (m, 4H, 2 CH2Ph), 4.72 (d, Jlf 2f = 3.5 Hz, 1H, H1f), 6. 38 (d, Jle, 2e = 3. 6 Hz, 1H, H1e), 7.25-7.38 (m, 10H, <BR> <BR> <BR> <BR> ArH), 8.57 (s, 1H, NH). Data for 41ß. Rf (hexane-AcOEt,<BR> <BR> <BR> <BR> <BR> <BR> <BR> 2: 1) = 0.27. [a] p + 66.8 (c 0.92, CHCl3). 1H NMR (200 MHz, CDCl3) d: 1.32 (s, 6H, iPr), 1.38 (s, 3H, iPr), 1.39 (s, 3H, iPr), 2.05 (s, 3H, Ac), 3.53 (dd, J2', 3' = 7. 5 Hz, J2@, = 3.4 Hz, 1H, H2'), 3.67 (dd, J2. 3 = 6. 1 Hz, J2 1 = 7.7 Hz, 1H, H2), 3. 71 (dd, Jazz 6b = 10.0 Hz, J6a, 5 = 5.6 Hz, 1H, (dd,J6b,6a=10.3Hz,J6b,5=6.8Hz,1H,H6b),H6a),3.94 4.08-4.38(m,8H,H,H,H,,H,H,H,H.,Hb), 2H,CH2Ph),4.83(dd,2H,CH2Ph),4.85(d,J1',2'4.74(dd, <BR> <BR> <BR> <BR> = 3.4 Hz, 1H, H1,), 5.72 (d, Jl, 2 = 7.8 H z, 1 H, H 1), 7.26- 7.41 (m, 10H, ArH), 8.63 (s, 1H, NH). Anal. Calcd. for C36H44Cl3NO12: C, 54.80; H, 5.62; N, 1.77. Found: C, 55.00; H, 5.76; N, 1.81.

O-(3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-ß- <BR> <BR> <BR> <BR> D-glucopyranosyl)-(1#6)-O-[2,4-di-O-benzyl-3-O-(tert-<BR& gt; <BR> <BR> <BR> <BR> <BR> <BR> butyldiphenylsilyl)-a-D-mannopyranosyl]- (1-4)-O- [6-0- (2- azido-3,6-di-O-benzyl-2-deoxy-a-D-glucopyranosyl)]- 2,3: 4, 5-di-O-cyclohexylidene-1-O-methoxycarbonyl-1-myo- inositol (42). A mixture of 281 mg (0.232 mmol) of 33, 147 mg (0.165 mmol) of 20 and powdered 4A molecular sieves in 3.3 mL of ethyl ether was stirred for 45 min at room temperature. At this time, 275 mL (0.030 mmol) of a solution of trimethylsilyl triflate in ethyl ether (0.108M) were added dropwise. The reaction mixture was stirred for 15 min, quenched with triethyl amine, diluted with CH2Cl2, filtered through celite, evaporated in vacuo and chromatographed (toluene/EtOAc 20: 1) to yield 42 (261 mg, 81%), 33 (44 mg, 18% referred to starting 33), and unreacted 20 (22 mg, 15 %)). Rf (hexane-EtOAc, 3: 1) = <BR> <BR> <BR> <BR> 0.46. M. p. = 104-107°C. [O (] D + 40.6 (c 1.31, CHCl3). 1H NMR (500 MHz, CDCl3) d: 0.69 (d, 3H, Mnt), 0.81 (d, 3H,

CH3Mnt), 0.83 (d, 3H, CH3Mnt), 0.90 (s, 9H, tBu), 0.91-<BR> <BR> <BR> <BR> <BR> <BR> 1.01 (m, 2H, Mnt), 1.08-1.15 (m, 1H, Mnt), 1.16-1.23 <BR> <BR> <BR> <BR> <BR> <BR> (m, 1H, Mnt), 1.30-1.70 (m, 23H, cyclohex., 3 Mnt),<BR> <BR> <BR> <BR> <BR> <BR> 1.85-1.92 (m, 1H, Mnt), 2.01-2.06 (m, 1H, Mnt), 2. 75 (bs, 1H, H2c), 3.13 (dd, J2b, 3b = 9.6 Hz, J2b,1b = 3. 4 Hz, 1H, <BR> <BR> <BR> <BR> H2b), 3.42-3.55 (m, 8H), 3.57 (dd, J5a,4a = 10.9 Hz, J5a,6a = 8.4 Hz, 1H, H5a), (m, 4H), 3. 65 (t, J4d,3d = J4d, 5d = 8.9 Hz, 1H, H4d), 3.79-3.87 (m, 3H), 3.95 (dd, J,,,=10.9Hz,J,,,=7.3Hz,1H,H,J, 4.08 (dd, J6a, 5a = <BR> <BR> <BR> <BR> 8.4 Hz, J6a,1a = 2.4 Hz, 1H, H6a), 4.12-4.18 (m, 2H), 4.21<BR> <BR> <BR> <BR> <BR> <BR> (dd, J2d, 3d = 10.3 Hz, J 2d, ld = 8.3 Hz, 1H, H2d), 4.32 (dd, J<BR> <BR> <BR> <BR> <BR> <BR> <BR> 3d, 2d 10.3 Hz, J 3d, 4d = 8.9 Hz, 1H, H3d), 4. 36 (t, J3a,4a =<BR> <BR> <BR> <BR> <BR> J3a za = 7.3 Hz, 1H, H3a), 4.39-4.52 (m, 6H), 4.53 (dd, J2a, 3a = 6.9 Hz, J2a,1a = 4.0 Hz, 1H, H2a), 4.67 (dd, 1H, <BR> <BR> <BR> <BR> CH2Ph), 4.87 (bs, 1H), 4.96 (dd, Jla 2a = 4.0 Hz, J1a,6a = 2.4<BR> <BR> <BR> <BR> <BR> <BR> Hz, 1H, Hla) 5. 13 (d, Jazz 2d = 8.3 Hz, 1H, H1d), 5. 25 (d,<BR> <BR> <BR> <BR> <BR> <BR> J1b, 2b = 3.4 Hz, 1H, H1b), 5.44 (s, 1H, H7d), 6.76-7.61 (m,<BR> <BR> <BR> <BR> <BR> <BR> 44H, ArH). 13C NMR (50 MHz, CDC13) d: 31,20.78, 21.92,23.17,23.60,23.73,23.90,24.77,25.06,25.93, 26.97,31.43,34.08,34.52,36.16,36.30,36.68,40.60, 44,71.23, 72.09,73.10,73.25,73.95,74.66,76.50,76.70,78.84, 19, 61,126.77,127.29,127.51, 127.72,127.91,127.97,128.10,128.20,128.26,128.95, 129.69,129.81,131.54,133.46,133.62,134.48,136.07, 137.46,137.75,138.05,138.59,154.16. Anal. Calcd. for <BR> <BR> <BR> <BR> C113H130N4O23Si : C, 69. 95; H, 6.75; N, 2.89. Found: C, 69.78; H, 6.85; N, 2.72.

O-(3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-ß- <BR> <BR> <BR> <BR> D-glucopyranosyl)-(1-6)-0-(2, 4-di-O-benzyl-3-a-D-<BR> <BR> <BR> <BR> <BR> <BR> mannopyranosyl0-(1#4)-O-[6-O-(2-azido-3,6-di-O-benzyl-2- deoxy-α-D-glucopyranosyl)]-2, 3: 4,5-di-O-cyclohexylidene-

1-O-menthoxycarbonyl-1D-myo-inositol (43). 6 mL of a 0.92M solution of tetrabutylammonium fluoride in THF buffered with acetic acid, were added to 71 mg (0.036 mmol) of 42. The reaction mixture was stirred for 10 days at 50°C, then cooled and quenched with water, diluted and extracted with CH2Cl2 and dried over Na2SO4.

Silica-gel column chromatography (hexane-EtOAc, 3: 1) afforded 43 (55 mg, 88% yield). Rf (hexane-EtOAc, 3: 1) 0.23. M. p. 103-105°C. [a] D + 37.9 (c 0.60, CHCl3). 1H NMR (300 MHz, C6D6) d: 0.69-0.71 (m, 1H, Mnt), 0.81 (d, 3H, CH3Mnt), 0.95 (d, 6H, CH3Mnt), 0.87-1.80 (m, 24H), 1.99-2.03 (m, 2H, Mnt), 2.13 (d, Jazz OH= 9. 5 Hz, 1H, OH), 2.15-2.27 (m, 2H, Mnt), 3.17 (dd, J2b, 3b = 10.4 Hz, J2b, lb = 3.5 Hz, 1H, H2b), (m, 2H), 3.62-3.65 (m, 1H), 3.67 (dd, J2c 3c = 3. 3 Hz, J2c 1c = 1.5 Hz, 1H, H2C) @ (m, 4H), 4.18 (dd, J3b,2b = 10. 2 Hz, Jb=9.0 Hz, lHt, H3b), 3.96-4.48 (m, 13H), 4.58 (dd, J ,=2.9 Hz, 1H, H6a), 4.68 (dd, J2,,, 3a = 6.7 Hz, a, ia = 4. 1 Hz, 1H, H2a), f 41*56-4.91 (m, 9H), 5.33 (s, 1H, H7d), 5. 40 (d, Jlc, 2c = 1.4 Hz, 1H, H1c), 5.44 (dd, La 2a = 3. 9 Hz, L71,,, sa = 3.1 Hz, 1H, Hua), 5.50 (d, Jld, 2d = 8.1 Hz, 1H, H1.), 5.69 (d, Jib, 2b = 3. 5 Hz, 1H, Hlb), 6.78-6. 83 (m, 2H, ArH), 6.85- 6.90 (m, 2H, ArH), 7.04-7.40 (m, 26H, ArH), 7.47-7.41 (m, 2H, ArH), 7.66-7. 69 (m, 2H, ArH). 13C NMR (50 MHz, C6D6) d: 23.94,24.10,24.35, 35.06,36.67,36.88, 37.08,40.89,47.50,56.35,63.21,66.42,68.57,68.83, 69.84,71.65,71.81,71.98,72.06,73.57,73.83,74.15, 74.87,75.30,76.32,76.72,77.04,77.25,77.43,77.96, 79.20,79.29,80.45,83.35,97.12,98.79,99.26,101.43, 112.15,113.48,118.92,123.26,126.65,127.70,128.98, 16,133.46,138.32,138.43, 138.62,138.75,139.30,139.37,154.90,167.91. Anal.

Calcd. for C97H112N4O23 : C, 68.46; H, 6.63; N, 3.29. Found :

C, 68.11; H, 6.55; N, 3.33. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>O-(6-O-Acetyl-2-O-benzyl-3,4-O-isopropylidene-α-D- <BR> <BR> <BR> <BR> <BR> <BR> <BR> galactopyranosyl)- (1-6)-O- (2-0-benzyl-3, 4-0-<BR> <BR> <BR> <BR> <BR> <BR> <BR> isopropylidene-α-D-galactopyranosyl)-(1#3)-O-[O-(3-O- benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-ß-D- <BR> <BR> <BR> <BR> glucopyranosyl)-(1-6)-]-0-(2, 4-di-O-benzyl-a-D-<BR> <BR> <BR> <BR> <BR> <BR> <BR> mannopyranosyl)-(1#4)-O-[6-O-(2-azido-3,6-di-O-benzyl-2- deoxy-a-D-glucopyranosyl)]-2,3: 4,5-di-O-cyclohexylidene- 1-O-menthoxycarbonyl-myo-inositol (44). A solution of 94 mg (0.119 mmol) of 41b, 45 mg (0.026 mmol) of 43 and activated powdered 4A molecular sieves in 0.6 mL of ethyl ether was stirred for 90 min at room temperature. At this moment, 37 mL (0.004 mmol) of a solution of trimethylsilyl triflate in ethyl ether (0.108M) were added. The reaction mixture was stirred for 45 min, quenched with triethyl amine, diluted with CH2Cl2, filtered through celite and evaporated in vacuo. Silica- gel column chromatography (2 x cyclohexane-Et20,5: 2) afforded 44a (44 mg) and 44ß (7 mg) in 83% total yield, 45 (2.3 mg, 5% referred to starting 43), 46 (35.5 mg, 38% referred to starting 41ß), and 47 (2.8 mg, 8% referred to <BR> <BR> <BR> <BR> starting 41p). 44a: Rf (hexane-EtOAc, 3: 1) = 0.26. M. p. : 93-96°C. [a] D + 54.1 (c 0.880, acetone). 1H NMR (500 MHz, C6D6,70°C) d: 0.62-0.71 (m, 1H, Mnt), 0.76 (d, 3H, CH3Mnt), 0.88 (d, 3H, CH3Mnt), 0.89 (d, 3H, CH3Mnt), 1.20 (s, 3H, iPr), 1.29 (s, 3H, iPr), 1.33 (s, 6H, iPr), 0.84- 1.78 (m, 24H), 1.74 (s, 3H, Ac), 1.89-1.93 (m, 2H, Mnt), 2.12-2.18 (m, 2H, Mnt), 3.35 (dd, Job, 3b = 10.4 Hz, <BR> <BR> <BR> <BR> J2b, 1b = 3-7 Hz, 1H, H2b), 3.44-3. 46 (m, 1H), 3.49 (t, J = 9.9 Hz, 1H, Hd), (m, 2H, H2e, Hd), 3.64 (dd, J2f, lf = 3-4 Hz, J2f, 3f = 7.6 Hz, 1H, H2f), (m, 2H, Ha), 3.96 (t, J = 9.2 Hz, 1H), 3.99-4. 01 (m, 2H, He), 4.06-4. 20 (m, 9H, Hf, Hd, H2CT Ha), 4.23 (t, J = 9. 6

Hz, 1H, Hb), 4.30-4.69 (m, 24H), 4.71 (dt, 1H, Mnt), (m, 4H, CH2Ph), 4.94 (d, J1f,2f = 3.1 Hz, 1H, H1f), 5.13 (d, J = 3.0 Hz, 1H, He), 5.3 (s, 1H, H7d), 5.33 (t Jazz 2a = 3-5 Hz, 1H, Hla), 5.42 (m, 1H, Hld), 5.58 (d, Jlb, 2b 3. 7 Hz, 1H, Hlb), 5.62 (d, Jlc 2c = 1. 8 Hz, 1H, Hlc), 6. 76-7.57 (m, 44H, ArH). 13C NMR (75 MHz, C6D6,50 °C) d: 16.67,20.52,20.84,21.99,23.79,24.14,24.24,24.38, 25.28,25.50,26.45,26.65,26.99,28.19,30.12,31.56, 34.38,35.14,36.75,37.03,37.23,41.01,47.63,56.47, 63.15,64.06,66.51,66.56,67.35,67.64,68.93,70.14, 71.34,71.79,72.63,72.79,73.52,73.66,73.89,74.01, 74.24,74.74,74.93,75.61,76.22,76.91,77.06,77.23, 77.48,78.02,78.16,78.81,79.31,80.97,83.42,97.56 (C1N3), 97.94 (ClMan, ClGal'), 99.36 (ClNPht), 99.43 (Benzylidene),108.94(iPr),109.56(iPr),(ClGal),101.57 112.16 (CHex), 113.42 (CHex), 123.36,126.69,127.03, 127.20ç 129.28,129.36,132.33,133.51,138.75,138.87, 138.94,139.03,139.50,139.65,154.88 (carbonate), 167,97 (NPht), 169.99 (Npht). 44 ß: Rf (hexane/EtOAc 3: 1) = 0. 25.' [a]0 + 38.1 (c 0.69, CHCl3). 1H NMR (C6D6, 500 MHz, 50°C): d 0.71-1.76 (m, 25H, cyclohex, 5H Mnt), 0.72 (d, 3H, CH3Mnt), 0.84 (d, 3H, CH3Mnt), 0.86 (d, 3H, CH3Mnt), 1.23 (s, 3H, iPr), 1.27 (s, 3H, iPr), 1.37 (s, 3H, iPr), 1.48 (s, 3H, iPr), 1.74 (s, 3H, CH3CO), 1.93- 1.98 (m, 2H, Mnt), 2.16-2.20 (m, 2H, Mnt), 3.08 (dd, J2b, 3b = 10. 2 Hz, J2b, lb = 3.7 Hz, 1H, H2b), 3.34-3.38 (m, 1H), 3.42-3.65 (m, 5H, 2Hd), 3.68-3.75 (m, 2H, Hf), 3.85-4.86 (m, 39H, H1e), 4.91-4.97 (m, 4H, Hlf), 5.29 (s, 1H, H7d), 5. 43-5. 46 (m, 3H, H1a, H1c, H1d), 5.48 (d, J2b, 3b = 3.8 Hz, 1H, H1b), 6.72-7.61 (m, 44H, ArH). 13C NMR (C6D6,75 MHz, 50 °C): d 16.4,20.6,20.9,22.0,23.5, 24.2,25.3,25.5,26.4,26.6,26.7,27.2,28.0,28.3, 30.1,31.4,34.3,35.0,36.7,37.0,40.9,47.5,56. 3, 63.7,64.1,66.4,68.8,70.0,71.5,71.9,72.4,72.9, 73.1,73.3,73.5,73.8,74.2,74.8,75.0,75.3,75.7,

76.9,77.5,77.7,79.1,80.0,83.5,97.4 (C-lb), 97.7 (C- lf), 99.0 (C-1c), 100.3 (C-le), 101.0 (C-ld), 101.5 (C- 7d), 109.5 (iPr), 109.8 (iPr), 112.2 (cyclohex), 113.4 (cyclohex), 123.3,126.7,127.5,128.0,128.4,129.3, 132.2,133.5,138.4,138.7,139.1,139.4,154.8 (OCO2), 168.9 (NCO), 170.0 (CH3CO). 45: Rf: 0.49 (hexane/EtOAc 2: 1). 1H NMR (CDCl3, 300 MHz): d 0.00 (s, 9H, (CH3) 3Si), 0.78-2. 09 (m, 29H, cyclohex, Mnt), 0.75 (d, 3H, CH3Mnt), 0.81 (d, 3H, CH3Mnt), 0.85 (d, 3H, CH3Mnt), 3.39-3. 41 (m, 2H, H2b, H2,,), 3.50-4. 00 (m, 14H), 4. 10 - 4.85 (m, 18H), 4.99 (dd, J1a,2a = 2. 7 Hz, J1a,6a = 3.9 Hz, 1H, H1a), 5.16 (d, J1c,2c = 2.0 Hz, 1H, H1c0, 5.20 (d, Jld, 2d = 8.0 Hz, 1H, Hld), 5.30 (d, Jlb, 2b = 3.2 Hz, 1H, H1b), 5.53 (s, 1H, H7d), 6.82-7.52 (m, 34H, ArH). 46: Rf: 0.27 (hexane/EtOAc 2: 1). 1H NMR (CDCl3, 200 MHz): d 1.29 (s, 3H, iPr), 1.34 (s, 3H, iPr), 1.35 (s, 3H, iPr), 1.50 (s, 3H, iPr), 2.06 (s, 3H, CH3CO), 3.47 (dd, J2f, 3f = 8.0 Hz, <BR> <BR> <BR> J2f, lf = 3.3 Hz, 1H, H2f), 3.56 (dd, J6, 6' = 10.3 Hz, J6,5= 4.3 Hz, 1H, H6), 3.81 (dd, J6', = 10.2 Hz, J6',5 = 7.7 Hz, 1H, H6'), 3.93 (dd, J = 4.6 Hz, J = 3.2 Hz, 1H, H4), 4.13- 4.48 (m, 7H), 4.52-4.58 (m, 1H), 4.66 (m, 2H, CH2Ph), 4.74 (m, 2H, CH2Ph), 4.78 (d, J1f,2f = 3.5 Hz, 1H, H1f) 5. 65 (dd, J1e,2e = 4. 6 Hz, L711,, NH = 8.5 Hz, 1H, H1e), 7.29- 7.41 (m, 10H, ArH), 8.57 (s, JAZZ le = 8. 5 Hz, 1H, NH). 47: Rf: 0.38 (hexane/EtOAc 2: 1). 1H NMR (CDCl3, 300 MHz): d 1.28 (s, 3H, iPr), 1.46 (s, 3H, iPr), 3.51 (dd, J6, = 7.6 <BR> <BR> <BR> Hz, J6, 5= 5.4 Hz, 1H, H6), 3.52 (s, 1H, H2), 4. 01 (d, J6', 6 =<BR> <BR> <BR> <BR> <BR> 7.6 Hz, 1H, H6'), 4.17 (d, J3, 4 = 7.0 Hz, 1H, H3), 4.39 (Yt, J4, 3 = 6.8 Hz, J4,5 = 6.0 Hz, 1H, H4), 4.44 (Yt, J5,4= 5.7 Hz, J5,6= 5.4 Hz, 1H, H5), 4.59 (dd, 2H, CH2Ph), 5.36 (s, 1H, H1), 7.18-7.30 (m, 5H, ArH). <BR> <BR> <BR> <P>O-(6-O-Acetyl-2-O-benzyl-3,4-O-isopropylidene-α-D- <BR> <BR> <BR> <BR> <BR> galactopyranosyl)-(1#6)-O-(2-O-benzyl-3,4-O-

isopropylidene-a-D-galactopyranosyl)- (1-3)-O- [O- (3-O- benzyl-4,6-O-benzylidene-2-deoxy-2-phtalimido-ß-D- <BR> <BR> <BR> <BR> glucopyranosyl)- (1-6)-]-O- (2, 4-di-O-benzyl-a-D-<BR> <BR> <BR> <BR> <BR> <BR> mannopyranosyl)- (1-4)-O- [6-O- (2-azido-3, 6-di-O-benzyl-2- deoxy-a-D-glucopyranosyl)]-2,3: 4,5-di-O-cyclohexylidene- 1-O-acetyl-l-D-myo-inositol (48). A solution of 44a (11.5 mg, 4.94 mmol) in 3: 2 tetrahydrofurane-methanol (2.2 mL) was treated at room temperature with 2.1 M aqueous lithium hydroxide (0.35 mL, 0.741 mmol). After 31h the reaction mixture was diluted with dichloromethane and washed with water, the water phase washed with dichloromethane and the combined organic phases dried over sodium sulphate and twice co-evaporated with toluene. The residue was suspended in chloroform (0.25 mL) and triethylamine (0.7 mL, 4.94 mmol) added to the suspension. After cooling at 0°C acetic anhydride (0.12 mL, 1.'23 mmol) and dimethylamino pyridine were added.

The reaction mixture was kept at room temperature for six days with further additions of triethyl amine and acetic anhydride as above every 24 h. The reaction mixture was diluted with dichloromethane, washed with water, the aqueous phase washed with dichloromethane and the combined organic phases washed with a saturated aqueous solution of sodium chloride and dried over sodium sulfate and evaporated. The residue was chromatographically purified. The NMR spectrum of the reaction mixture revealed it to be a 5.5: 1 mixture of 48 and an intermediate compound and the mixture was therefore solved in chloroform (0.25 mL) treated with triethyl amine (0.7 mL, 4.94 mmol), cooled at 0°C, treated with acetic anhydride (0.12 mL, 1.23 mmol) and dimethylamino pyridine and warmed at 40°C. The reaction mixture was kept at this temperature for four days, cooled at room temperature, and worked up as above to give 8.4 mg (78%)

of 48. 1H NMR (500 MH2, C6D6,50°C) d 1.27 (s, 3H, iPr),<BR> <BR> <BR> <BR> <BR> <BR> 1,35 (s, 3H,'Pr), 1.41 (s, 3H, iPr), 1.44 (s, 3H, iPr),<BR> <BR> <BR> <BR> <BR> 1.78 (s, 3H, CH3Co), 1.79 (s, 3H, CH3Co), 1.30-1.86 (m, 20H, cyclohex), 3.43 (dd, J2b, 3b= 10.0 Hz, J2b, 1b=3.7 Hz, <BR> <BR> <BR> 1H, H2b), 3.48-3.58 (m, 2H), 3.63-3.71 (m, 2H, H5d), 3.65 1e=3.5Hz,J2e,3e=7.6Hz,1H,H2e),3.72(dd,J2f,(dd,J2e, lf= 3.6 Hz, J2f, 3f= 7. 7 Hz, 1H, H2f), 3.77 (dd, J= 8.7 Hz, J= 10.2 Hz, 1H, H5a), 3.79 (dd, J= 6.0 Hz, J= 10. 1 Hz, <BR> <BR> <BR> <BR> 1H), 4.04 (t, J= 8.9 Hz, 1H), 4.07-4.12 (m, 3H, H4e, H4d,<BR> <BR> <BR> <BR> <BR> H6d), 4.15 (dd, J= 2. 4 Hz, J= 5.5 Hz, 1H, H4f), 4.17-4.21<BR> <BR> <BR> <BR> <BR> (m, 2H), 4. 22 (s, 1H, H2c), 4.25-4.36 (m, 7H, H3at H4a,<BR> <BR> <BR> <BR> <BR> H3b), 4.38-4.49 (m, 6H, H6a, H3d, H3,), 4.52-4.78 (m, 15H, H2d,H6d),4.87(d,1H,CH2Ph),4.98(dd,2H,H2a,H3f, <BR> <BR> <BR> <BR> CH2Ph), 5.00 (d, Jlf, 2f= 3. 5 Hz, 1H, H1f), 5.13 (d, 1H,<BR> <BR> <BR> <BR> <BR> CH2Ph), 5.20 (d, Jle 2e= 3.4 Hz, 1H, H1e), 5.36 (s, 1H, H7d)<BR> <BR> <BR> <BR> <BR> 5.47-5. 50 (m, 2H, H1a, H1d), 5. 60 (d, Jlb, 2b= 3.7 Hz, 1H,<BR> <BR> <BR> <BR> <BR> Hlb), 5. 76 (d, Jlc 2c= 2. 0 Hz, 1H, Hl), 6.80-7.66 (m, 44H, ArH).

13C NMR (C6D6,125 MHz, 50°C): d 3,23.6,23.9, 7,36.7, 2,67.0,67.3,68.6, 4,73.6,73.7,74.0, 3,76.0,76.6,76.7,76.8,76.9,77.2,77. 4, 5,80.6,83.1,97.4 (C1), 97.5 (C1), 97.6 (C1), 99.0 (C1), 101.3 (C7d), 108.7 (Cipso), 110.0 (Cipso), 111.5 (Cipso), 113.0 (Cipso), 0,127.1, 3,127.4,127.5,127.6,127.6, 8,127.8,127.9,128.0,128.0,128.1,128.2, 3,128.4,128.4,128.7,132.0,133.3, 6,138.6,138.7,139.2,139.4,169.1, 169.7. <BR> <BR> <BR> <P>O-(6-O-Acetyl)-2-O-benzyl-3,4-O-isopropylidene-α-D -<BR> <BR> <BR> <BR> <BR> <BR> galactopyranosyl)- (1-6)-O- (2-0-benzyl-3, 4-0-

isopropylidene-a-D-galactopyranosyl)-(l-3)-O- [0-(l-3)-O- [0- (2- <BR> <BR> <BR> <BR> acetamido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-a-D-<BR> ; <BR> <BR> <BR> <BR> <BR> <BR> glucopyranosyl-(1#6)-]-O-(2,4-di-O-benzyl-α-D-<BR> <BR> <BR> <BR> <BR> <BR> <BR> manopyranosyl)-(1#4)-O-[6-O-(2-azido-3,6-di-O-benzyl-2-<B R> <BR> <BR> <BR> <BR> <BR> <BR> deoxy-a-D-glucopyranosyl)]-2, 3: 4, 5-di-O-cyclohexylidene-l- 0-acetyl-l-D-myo-inositol (49). To a solution of 48 (8.4 mg, 3.84 mmol) n-butyl alcohol (0.77 mL) ethylenediamine (167 mL, 2.50 mmol) was added at room temperature. After 90 minutes the temperature was raised to 90°C and the reaction mixture was kept at this temperature for 18h, then cooled, evaporated and the residue co-evaporated twice with toluene. The residue was solved in chloroform (0.25 mL), treated with triethyl amine (0.8 mL, 5.76 mmol) and the solution cooled to 0°C before adding acetic anhydride (0.25 mL, 2.69 mmol) and a catalytic amount of dimethylamino pyridine. The reaction mixture was allowed to warm and kept at room temperature for 20h, then the solvent was evaporated and the residue purified by column chromatography (2: 1 hexane-ethyl acetate) to give pure 49 (7.5 mg, 93%). 1HRMN (C6D6, 500 MHz, 50°C): d 1.29 (s, 3H, iPr), 1.38 (s, 3H, iPr0, 1. 42 (s, 6H, 2'Pr), 1.78 (s, 3H, CH3CO), 1. 81 (s, 3H, CH3CO), 1.25-1.84 (m, 23H, cyclohex, CH3CO), 3.22-3.31 (m, 1H, H2d), 3.34-3.39 (m, 1H, H2b), (m, 1H, H5d), 3.57 (t, J6d, sd J6d, 6d 10.0 Hz, 1H H6d), 3.61-3.66 (m, 1H, H4d), 3.73-3.77 (m, 3H, Hsa, Hé, H2f), 3.79-3.84 (m, 1H, H6e), 3.86-3.90 (m, 1H), 4.06 (d, 10.2Hz,1H6b),4.15-4.19(m,3H,H4f,H6d,H6e),J6b,6b= 4.21-4.44 (m, 12H, H4e, H6b, H3a, H4ar H3b, H2e, H6a, H3cr H4b), 19H,H5b,H3e,H3f,H2a,H3d,H4f,H5e),4.98(d,4.50-4.87(m,.

1H, CH2Ph), (m, 4H, CH2Ph, Hld, H1f), 5.21 (d, JNH, 2d= 6.7 Hz, 1H, NH), 5. 38 (d, Jale, 2e= 3.3 Hz, 1H, H1e), 5. 40 (s, 1H, H7d) 5. 44 (d, 1H, CH2Ph), 5.45 (t, J1a, 2a= J1a, 2a= J1a, 6@=1H,H1a),5.55(d,J1b,2b=3.2Hz,1H,H1b),5.91Hz, (s, 1H, H1c), (m, 40H, ArH).

13C NMR (C6D6, 125 MHz, 50 °C): d 20.2,20.3,23.6,23.9, 24.0,25.0,25.1,26.2,26.6,27.9,28.0,34.7,36.7, 36.9,37.1,59.1,63.0,63.8,65.9,66.3,67.2,67. 4, 68.9,69.4,71.3,71.4,72.5,72.6,73.6,73.6,73.7, 73.8,73.9,74.4,74.5,74.7,76.2,76.6,76.7,76.8, 4, (C1b) 97.7 (C1d, C1f), 98.1 (C1c), 100.3 (Cle), 101.3 (C7d), 108.8 (Cipso, iPr), <BR> <BR> <BR> 109.3 (Cipso, iPr), 111.5 (Cipso, cyclohex), 113.0 (Cipso, cyclohex), 126.4,127.3,127.4,127.6,127.8,127.8, 127.9,127.9,128.0,128.0,128.1,128.2,128.2,128.2, 128.2,128.3,128.3,128.4,128.4,128.6,138.3,138.5, 138.6,138.7,139.2,139.2,169.1,169.8. <BR> <BR> <BR> <BR> <BR> <BR> <P>0-(2-O-Benzyl-3, 4-O-isopropylidene-a-D-galactopyranosyl)-<BR> <BR> <BR> <BR> <BR> <BR> (1-6)-0-(2-O-benzyl-3, 4-O-isopropylidene-a-D-<BR> <BR> <BR> <BR> <BR> <BR> galactopyranosyl)-(1#3)-O-[O-(2-acetamido-3-O-benzyl-4,6-< ;BR> <BR> <BR> <BR> <BR> <BR> O-benzylidene-2-deoxy-ß-D-glucopyranosyl)-(1#6)-]-O-(2,4-&l t;BR> <BR> <BR> <BR> <BR> di-O-benzyl-a-D-mannopyranosyl)-(1-4)-0-[6-O-(2-azido- 4,5-di- O-cyclohexylidene-lD-myo-inositol (50). To a solution of 49 (9.8 mg, 4.67 mmol) in 3: 7 tetrahydrofuran-methanol (0.5 mL) a 0.2 M solution of sodium methoxide in methanol (70 mL, 14.0 mmol) was added at room temperature. After 8h the reaction mixture was neutralised with Dowex 50WX resin, filtered and evaporated. The residue was purified by column chromatography (3: 2 hexane-ethyl acetate) to give 50 (8.6 mg, 91%). lH RMN (C6D6,500 MHz, 50°C): d 1.31 (s, 3H,'Pr), 1.33 (s, 3H, iPr), 1.39 (s, 3H, iPr), 1.43 (s, 3H, iPr), 1.22-1.43 (m, 5H, cyclohex), 1.45-1.75 (m, 18H, cyclohex, CH3CO), 1.05 (s, 1H, OH), 2.69 (d, loH, la= 2.3 Hz, 1H, OH), 3.24-3.28 (m, 1H, H2d), 3.30-3.34 (m, 1H, (m,1H,H5d),3.57(t,J6d,5d=J6d,6d=10.03.48-3.53 Hz, 1H, H6d), 3.61-3.66 (m, 1H, H4d), 3.73 (dd, J2f, lf= 3.6 Hz, J2f, 3f= 7.4 Hz, 1H, H2f), 3.75 (dd, J= 8.5 Hz, J= 10.1

Hz, 1H, H5a), 3.82 (dd, J2, 1e= 3.4 Hz, J2e, 3e= 7.4 Hz, 1H, H2e), 3.85-3.91 (m, 2H, H4c), 3.94-4.01 (m, 2H, H6e), 4.04 (d, J6b, 6b= 11. 3 Hz, lH6b), 4.10-4.16 (m, 3H, H4f, Hl,, H6e), 4.19-4.23 (m, 3H, H6d), 4.24 4. 04 (dd, J6b, 5b= 2.9 Hz, J6b, 6b= 11.1 Hz, 1H6b), 4.29-4.56 (m, 14H, H2a, H3, H4a, H6a, H3c, H2c, H5bH3f,H4e),4.65-4.86(m,9H,H3e,H3d,H5e),H4b, 4.99 (d, 2H, CH2Ph), 5.07 (d, Jlf, 2f= 3.5 Hz, 1H, H1f), 5.08 (d, 1H, CH2Ph), 5.17-5.19 (m, 2H, Hld, H1b), 5. 23 (d, JNH, 2d= 7.1 Hz, 1H, NH), 5.41 (d, 1H, CH2Ph), 5.41 (s, 1H, H7d), 5. 42 (d, J1e, 2e= 3-2 Hz, 1H, H1e), 5.83 (s, 1H, H1c), 7.14- 7.65 (m, 40H, ArH).

13C NMR (C6D6,125 MHz, 33°C): d 20.7,23.2,23.5,23.8, 23.9,24.0,24.1,25.0,25.1,26.2,26.4,27.9,28.0, 33.6,36.6,36.6,36.9,59.2,62.5,62.8,65.8,67.4, 67.9,68.9,69.2,71.3,71.4,72.6,72.8,73.0,73.6, 73.8,74.1,74.4,75.7,76.1,76.4,76.4,76.7,76.8, 77.2, @77. 3,77.4,78.5,80.6,83.3,96.8, (Cl), 98.2 (C1), 98.5 (Cl), 100.0 (C1), 101.3 (C7d), 108.9 (Cipso, Pr), 109.1, (Cipso, iPr), 111.1 (Cipso, cyclohex), 126.5, 127.7,128.1,128.2,128.3,128.4,128.6, 128.7,138.3,138.4,138.7,138.8,139.3,169.8.

References: The references cited herein are all incorporated by reference.

[1] G. Romero and J. Lasner, Advan. Pharmacol., 24 (1993) 21-50 and references therein.

[2] 1. Varela-Nieto, Y. Leon, and H. N. Caro, Comp.

Biochem. Physiol., 115B (1996) 223-241.

[3] P. Stralfors, Bioessays, 19 (1997) 327-335.

[4] M. C. Field, Glycobioloqy, 7 (1997) 161-168.

[5] D. R. Jones and I. Varela-Nieto, Int. J. Biochem.

Cell Biol., 30 (1998) 313-326.

[6] J. M. Mato, K. Kelly, A. Abler, L. Jairett, B. E.

Corkey, B. E. Cashel and D. Zopf, Biochem. Biophys.

Res. Commun., 146 (1987) 764-770.

[7] J. Larner, L. C. Huang, C. F. W. Schwartz, A. S. Oswald, T. Y. Shen, M. Kinter, G. Tang and K. Zeller, Biochem. Biophys. Res. Commun., 151 (1988) 1416- 1426.

[8] L. C. Huang, M. C. Fonteles, D. B. Houston, C. Zhang, and J. Larner, Endocrinology, 132 (1993) 652-657.

[9] J. Larner, P. J. Roach, L. C. Huang, G. Brocker, F.

Murad and R. Hazen, Adv. Exp. Biol., 111 (1979) 103- 112.

[10] H. N. Caro, A Guadano, M. Bernabe, M. Martin-Lomas, J. M. Mato, R. A. Dwek and T. W. Rademacher, Glycoconiuaate J., 10 (1993) 242.

[11] G. Romero, G. Gomez, L. Huang, K. Lilley and L.

Lutrell, Proc. Natl. Acad. Sci. USA, 87 (1990) 1476- 1480.

[12] J. Represa, M. A. Avila, C. Miner, F. Gisaldez, G.

Romero, R. Clemente, J. M. Mato and I. Varela-Nieto, Proc. Natl. Acad. Sci. USA, 88 (1991) 8016-8019.

[13] A. Zapata and M. Martin-Lomas, Carbohydr. Res., 234 (1992) 93-106.

[14] A. Zapata, Y. Leon, J. M. Mato, I. Varela-Nieto, S.

Penartés and M. Martin-Lomas, Carbohydr. Res., 264 (1994) 21-31.

[15] C. Jaramillo, J. L. Chiara and M. Martin-Lomas, J.

Orq. Chem., 59 (1994) 3135-3141.

[16] N. Khiar and M. Martin-Lomas, J. Orq. Chem., 60 (1995) 7017-7021.

[17] H. Dietrich, J. F. Espinosa, J. L. Chiara, J. Jimenez- Barbero, Y. Leon, I. Varela-Nieto, J. M. Mato, F. H.

Cano, C. Foces-Foces and M. Martin-Lomas, Chem. Eur.

J., 5 (1999) 320-336.

[18] R. D. Groneberg, T. Mizayaki, N. A. Stylianides, T. J.

Schulze, W. Stahl, E. P. Schreiner, T. Suzuki, Y.

Iwabuchi, A. L. Smith and K. C. Nicolau, J. Am. Chem.

Soc., 115 (1993) 7593-7611.

[19] K. C. Nicolau, R. E. Dolle, D. P. Papakatjis and J. L.

Randall, J. Am. Chem. Soc., 106 (1984) 4189-4192.

[20] Vft Pozsgay and H. J. Jennings, J. Org. Chem., 53 (1988) 4042-4052.

[21] D. S.' Brocon, S. V. Ley, S. Vile and M. Thompson, Tetrahedron. 47 (1991) 1329-1342.

[22] D. Khane, S. Walker, Y. Cheng and van Engen, J. Am.

Chem. Soc., 111 (1989) 6881-6882.

[23] R. R. Schmidt and W. Kinzy, Advan. Carbohydr. Chem.

Biochem., 50 (1994) 21-123.

[24] For a review, see B. V. L. Potter and D. Lampe, Anal.

Chem. Int. Edn. Enal., 34 (1995) 1933-1979.

[25] A. Zapata, R. Fernández de la Prahilla, M. Martin- Lomas and S. Penartés, J. Org. Chem., 56 (1991) 444- 447.

[26] A. Aguiló, M. Martin-Lomas and S. Penartés, Tetrahedron Lett., 33 (1992) 401-404.

[27] S. David and S. Hanessian, Tetrahedron, 41 (1985) 643-663.

[28] R. C. Mehrotra and V. D. Gupta, J. Organometal. Chem., 4 (1965) 2370-

[29] R. Poster, K. L. Amen and W. V. Dahlhoff, Liebias.

Ann. Chem., (1975) 752.

[30] K. M. Taba, R. Poster and W. V. Dahlhoff, Synthesis, (1984) 399-401.

[31] P. J. Garegg, T. Ivessen, R. Johansson and B.

Lindberg, Carbohydr. Res., 130 (1984) 322-326.

[32] B. Kratzer, T. G. Meyer and R. R. Schmidt, Tetrahedron Lett., 34 (1993) 6881-6884.

[33] R. H. Lemieux and R. M. Ratcliffe, Can. J. Chem., 57 (1979) 1244-1251.

[34] N. V. Bovin, S. E. Zurabyan and A. Y. Khorlin, Carbohydr. Res., 98 (1981) 25- [35] H. Paulsen and W. Stenzel, Chem. Ber., 111 (1978) 2334- [36] M. Kloorterman, M. P. de Niijs and H. van Boom, J.

Carbohydr. Chem., 5 (1986) 215- [37] A. Vasella, C. Witzig, J. L. Chiara and M. Martin- Lomas, Helv. Chim. Acta, 74 (1991) 2073-2077.

[38] R. J. Ferrier and R. H. Furneaux, Carbohydr. Res., 52 (1976) 63-68.

[39] J. Gelas, Adv. Carbohydr. Chem. Biochem., 39 (1981) 71-156.

[40] P. J. Garegg, H. Hultberg and S. Wallin, Carbohvdr.

Res., 108 (1982) 97-101.

[41] R. Johansson and B. Samuelsson, J. Chem. Soc.

Perlaz. Trans. 1, (1984) 2371-2374.

[42] M. Naruto, K. Ohno, N. Narusa and H. Takeuchi, Tetrahedron. Lett., (1979) 251-254.

[43] E. J. Corey, H. Cho, C. Rocker and D. H. Hua, Tetrahedron Lett., 22 (1981) 3455-3458.

[44] E. J. Corey and A. Venkateswarlu, J. Am. Chem. Soc., 94 (1972) 6190-6191.

[45] A. Fernandez-Mayoralas, A. Marra, M. Trumtel, A.

Veysieres and P. Sinaij, Carbohydr. Res., 188 (1989) 81-95.

[46] T. Ogawa, S. Nakabayashi and K. Kasajima, Carbohydr.

Res., 95 (1981) 308-312.

[47] Suzuki, Tetrahedron Lett., 30 (1989) 6879-6882 and 29 (1988) 3567-3574.

[48] Frick et al, in Biochemistry, 37, (1998), 13421- 13436.